Download Miles Stanford - EMA

Curriculum vitae
PERSONAL INFORMATION
Miles Stanford
WORK EXPERIENCE
October 1978–March 1979
HS Orthopaedic/General Surgery
St Giles Hospital, Camberwell (United Kingdom)
March 1979–August 1979
HP General Medicine
King's College Hospital, Camberwell (United Kingdom)
September 1979–March 1980
SHO Accident & Emergency
Ashford Hospital, Middlesex (United Kingdom)
October 1980–April 1981
SHO Neurosurgery
Brook General Hospital, Woolwich (United Kingdom)
April 1981–October 1981
SHO Ophthalmology
Greenwich District Hospital, Greenwich (United Kingdom)
November 1981–October 1983
SHO/Registrar Ophthalmology
St Thomas' Hospital, Lambeth (United Kingdom)
November 1983–April 1984
Registrar Ophthalmology
Sutton Eye Hospital, Surrey (United Kingdom)
May 1984–October 1984
Clinical Assistant Ophthalmology
Moorfields and St Thomas' Hospital (United Kingdom)
October 1984–November 1986
Research Associate, Dept of Immunology
Rayne Institute, St Thomas' Hospital (United Kingdom)
October 1984–November 1986
Joint Senior Registrar Ophthalmology
King's College Hospital and Moorfields (United Kingdom)
November 1986–June 1990
Honorary Research Associate, Ocular
Immunology, St Thomas' Hospital (United Kingdom)
July 1990–July 1995
Iris Senior Clinical Research Fellow
Dept Ocular Immunology, St Thomas' (United Kingdom)
July 1990–Present
Honorary Consultant Ophthalmologist
Queen Mary’s Hospital Sidcup (United Kingdom)
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page1 / 26
Curriculum vitae
July 1995–September 1999
Miles Stanford
Iris Fund Senior Lecturer and Honorary Consultant
Dept Academic Ophthalmology, St Thomas' Hospital (United Kingdom)
September 1999–September
2004
Iris Fund Reader and Honorary Consultant
September 2004–November
2010
Professor of Clinical Ophthalmology
November 2010–Present
Department of Academic Ophthalmology GKT (United Kingdom)
Kings College, London (United Kingdom)
Consultant Ophthalmologist
GSTT NHS Foundation Trust (United Kingdom)
November 2010–Present
Honorary Professor Ophthalmology
KCL (United Kingdom)
September 2011–Present
Consultant Ophthalmologist
Behcet’s Disease National Centre of Excellence Bart’s Healthcare Trust (United Kingdom)
2012–Present
Clinical Lead Ophthalmology
St Thomas’ Hospital (United Kingdom)
EDUCATION AND TRAINING
–June 1976
MEDICAL SCIENCES TRIPOS (Cantab)
–June 1978
B. CHIR
–March 1979
M.A., M.B.
–October 1980
Primary FRCS (Eng/Edin)
–January 1983
Diploma Ophthalmology (Eng)
–October 1984
FRCS Ophthalmology (Eng)
–
MSc Medical Immunology, London - distinction
(United Kingdom)
–April 1989
–December 1989
F.R.C.Ophth.
Accreditation Higher Surgical Training (Ophthalmology)
Royal College Surgeons (United Kingdom)
–March 1994
11/3/16
M.D. (Cantab)
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page2 / 26
Curriculum vitae
–
Miles Stanford
Recognised Teacher
University of London (United Kingdom)
–September 1999
Approved Teacher
University of London (United Kingdom)
–May 2011
FRCP London
(United Kingdom)
–November 2013
Revalidated GMC
ADDITIONAL INFORMATION
Expertise
CURRENT RESEARCH INTERESTS
At the moment I am involved in a wide variety of clinical laboratory and experimental studies broadly
relating to intra-ocular inflammation and particularly to the interaction between cells of the immune
system and the retina through the blood retinal barriers. Because of my clinical and research
background I am able to bridge the gap between the clinic and the research laboratory thus providing
a clinical focus to experimental studies and vice versa. The disorders that I principally study are three,
each of which causes retinal vascular leakage due to inflammation. The first is idiopathic retinal
vasculitis where there is no obvious systemic inflammation outside the eye, the second, Behcet’s
disease, where intra-ocular inflammation occurs as part of a more widespread inflammatory diathesis
and the third toxoplasma retinochoroiditis where breakdown of the blood-retinal barrier can be directly
attributed to intra-ocular infection. In each case the end result is the same, with increased leucocyte
and plasma leakage into the retina causing visual loss, but through different mechanisms.
Natural history studies of diseases causing blood-retinal barrier breakdown
I am currently involved in a number of studies looking at the epidemiology and long-term outcome of
patients with intra-ocular inflammation. The realisation that our patients who present with idiopathic
(that is without evidence of systemic disease) posterior uveitis will develop systemic features within
five years has been a major thrust of such studies. For instance, we have found that one third of
patients who show predominant leakage of their retinal vessels on presentation are likely to develop
symptoms and signs of multiple sclerosis within five years. Conversely, patients who have a
predominantly ischaemic picture within the eye on presentation tend to develop systemic thrombosis
(either myocardial infarct or completed stroke) within five years and this is a particularly relevant risk
since the mean age of presentation of these patients is 29 years (1). We have recently demonstrated
in a ten year follow-up study of patients who present with uveitis associated with sarcoidosis, both the
rate of intra-ocular complications (glaucoma, cataract) and new organ involvement (2). The relevance
of these studies in relation to the laboratory and experimental studies described below lies in the ability
to accurately phenotype patients for further therapeutic studies. We have also evaluated the
epidemiology and severity of ocular disease in patients with Behcet’s disease in the UK and in the
Middle East (3)
Over the last ten years I have carried out a number of epidemiological investigations into the incidence
of toxoplasma retinochoroiditis. This has principally involved collaboration with Professor R Gilbert,
Department of Biostatistics and Epidemiology, Institute of Child Health, as well as other
ophthalmological colleagues in the UK. Our current findings throw serious doubt on the previous
dogma that all new eye disease arises as reactivation of congenital disease and the implications of
this for public health strategies are currently being evaluated. In addition, I was one of the principal
advisers in the ophthalmological arm of the European Multicentre study of congenital toxoplasmosis, a
European funded collaboration in twelve centres looking at long-term outcome in children congenitally
infected with this disease. . I have recently been appointed as a panelist to the Toxoplasma Prevention
Project, an EEC funded consensus review body, to set the research agenda for toxoplasma research
in Europe over the next 5 years. Recent studies have included the prospective surveillance of children
presenting to both ophthalmologists and paediatricians with symptomatic disease with the intriguing
finding that children are reported under 4 years old and over 10 but very rarely between these times.
Epidemiological studies have also compared the rate of retinochoroiditis in congenitally affected
children in Europe and Brazil with the finding that children in Brazil are much more likely to develop
eye disease and in a much more severe form. Furthermore I currently actively collaborate with
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page3 / 26
Curriculum vitae
Miles Stanford
colleagues in the US (Prof G Holland UCLA) in the genetics of parasite pathogenicity and clinical
presentation.
Imaging studies of blood-retinal barrier breakdown
I have been interested in new modalities of ocular imaging in patients with uveitis and have led a
research group looking at ways of using these new techniques in the study of intra-ocular
inflammation. Since the eye is the only place in the body where the interaction between blood and
nervous tissue can be directly observed, the development of in vivo methods to look at changes in the
blood retinal barrier and leucocyte trafficking have been and will be fundamental to our understanding
of the immunopathology of inflammation at this site. To date I have been involved in both clinical and
experimental studies of fluorescein angiography, indocyanine green angiography (4) and optical
coherence tomography (5 and 10) in the assessment of intra-ocular inflammation. The recent
development of optical coherence tomography has allowed a much more detailed analysis of fluid
changes occurring within the retina secondary to ocular inflammation and currently we are studying
longitudinally the value of this in the assessment of our patients as well as the role of acetazolamide in
speeding this fluid movement. .
Clinical laboratory studies of blood retinal barrier breakdown
Over the last ten years I have been interested in the assessment of anti-retinal autoimmunity, in
particular anti-retinal antibodies in relation to intra-ocular inflammation. Whilst the production of these
organ-specific antibodies is probably an epiphenomenon to retinal damage in these patients in a large
proportion of cases, in others, particularly in neoplastic syndromes, their appearance appears to be
primarily pathogenic. Furthermore, in the search for the primary event that encourages leucocyte
traffic across the blood-retinal barrier in intra-ocular inflammation, the role of antibody and complement
has been largely ignored which is surprising since both electrophysiological and pathological evidence
points to this being a prime mover in the process. Currently we have just completed a study evaluating
the value of measuring anti-retinal antibodies in patients with toxoplasma retinochoroiditis (7) and we
provide a tertiary service for the analysis of anti-retinal antibodies in those rare patients with cancer
associated retinopathy. Recent clinical laboratory studies have also included an examination of the
hypothalamic pituitary adrenal axis in relation to ocular outcome and steroid usage as well as the
value of urinary neopterin as a marker for impending relapse in this disease (1).
Current cellular studies are directed towards the elucidation of the interaction between leucocytes and
the retinal vascular endothelium. This has involved the development of methods for the in vivo
observation of leucocyte trafficking (see above) as well as in depth immuno-pathological analysis of
the expression of adhesion molecules. These studies have highlighted the important role played by
cytokines and chemokines in the attraction and diapedesis of inflammatory cells at the blood retinal
barrier (8). Furthermore, in our clinical studies, the value of measuring soluble forms of these adhesion
molecules has been shown in that raised levels are observed in patients with active relapse and these
come back to normal values with the appropriate treatment. Given that intraocular inflammation can
be measured in cubic millimetres this is a somewhat surprising observation since the analysis of these
molecules is done in whole blood. Unfortunately longitudinal studies have not revealed any value for
the measurement of these markers to predict relapse in the short-term or determine visual outcome in
the long-term.
A major area of ignorance in the pathogenesis of intra-ocular infection by Toxoplasma gondii is how
the organism accesses the retina in the first place and secondly what mechanisms are employed by
retinal cells that make them either resistant or susceptible to infection. To answer this question we are
currently looking at the mechanisms of infectivity and resistance in retinal cells (retinal vascular
endothelium, Muller cells and retinal microglia) grown in vitro. Preliminary work has again shown the
importance of cytokines and chemokines in the reaction of these cells to infection (9) and we are now
employing micro-array analysis to study up- and down-regulation of genes in response to infection.
Genetic studies of diseases causing breakdown of the blood retinal barrier
In general, intra-ocular inflammatory syndromes are not diseases that run in families. However,
several of them have been shown to be closely associated with certain MHC haplotypes and the
analysis of this association could provide new clues into the immuno-pathogenesis of the condition.
Recently we have been involved in an extensive HLA analysis of our patients with idiopathic
intraocular inflammation to see whether certain haplotypes could provide additional risk factors for the
subsequent development of systemic disease or for a bad ocular outcome. In addition, we are
currently performing a major genotypic investigation into patients from the Middle East with Behçet’s
syndrome (in conjunction with Dr R Vaughan, Immunogenetics Laboratory, Guy’s Hospital, Professor
S Ohno, Hokkaido University, Japan, and our clinical colleagues in the Jordan Hospital, Amman,
Jordan, The Eye and Ear Infirmary, Damascus and St John Ophthalmic Hospital, Jerusalem). As well
as standard Class I and Class II genotyping, we have also looked at HLAB51 subtypes and the
prevalence of polymorphisms of genes governing TNF and ICAM production as well as alleles of nonClass I HLA molecules (MICA) (3). Furthermore, we have looked at single nucleotide polymorphisms
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page4 / 26
Curriculum vitae
Miles Stanford
of genes that control cytokine and chemokine production. The identification of associations between
these mutations and the form and outcome of intra-ocular inflammation will be important not only in
explaining the chronicity of disease but also in terms of developing more tailored therapeutic
approaches. The recent identification of several well characterised families with Behçet’s disease has
highlighted the relevance of these studies and we now intend to proceed to large scale genomic
mapping in these families in order to assess the value of disease related genes other than those on
chromosome 6. A recently completed whole genome association study has confirmed the importance
of HLA B*51 and, interestingly, polymorphisms in the IL-10 gene. In addition, we are studying at the
cellular level (with Prof A Hayday, Dept Immunobiology, Guy’s Hospital) the interaction of alleles of
MICA and HLA B*51 in the activation of NK cells to try and determine the functional relevance of these
alleles to the pathogenesis of disease (12).
Therapeutic studies to ameliorate inflammatory breakdown of the blood retinal barrier
The only way at present to control intra-ocular inflammation is to use high doses of
immunosuppressive drugs. Whilst usually effective, these agents have significant side-effects and
there is an urgent need for more tailored therapy. We have recently completed an analysis of our
patients receiving azathioprine as second-line immunosuppression showing the value of this
treatment as a steroid-sparing agent in these patients. Current studies are evaluating the use of depot
steroid injections into the eye (11) as well as the use of slow release steroids contained within a
capsule and sewn into the eye. Both methods have the advantage of being extremely effective and of
not causing significant systemic toxicity. The mechanism by which the effect occurs will be a further
research goal since such local treatment is also effective in curing leakage due to blood-retinal barrier
breakdown from other causes not thought to be immunologically mediated (ie in diabetic retinal
oedema or that occurring after retinal vein occlusion) I have recently completed a systematic review of
the effectiveness of antibiotics used to treat toxoplasma retinochoroiditis. This review has shown that
none of the treatments currently available are effective; indeed, there is an up to 30% adverse effect
rate. In addition, I have made original clinical observations in that patients with this disease rarely
show cystoid macular oedema despite profound intraocular inflammation
Supervisor to students working in the field:
(1) Ms H Palmer MD Univ London, (2) Mr C Edelsten MD Univ Cambridge, (3) Mr D Verity MD Univ
London, (4) Ms L Howe MD Univ London, (5) Mr R Antclife MD Univ London, (6) Mr A Parnaby-Price
MD Univ London, (7) Mr R Whittle MSc Univ London, (8) Mr I Subak-Sharpe MD Univ Cambridge, (9)
Ms C Brunton PhD Univ London (10) Ms L Pelosini MD Univ London (11) Mr A Nazar Univ Aleppo
(12) Ms S Shafi PhD Univ London (13) Mr H Petrushkin London, (14) Mr Allon Barsam Cambridge,
(15) Mr Anish Dhital London, (16) Mr Robert Petrarca London
Current objectives
As can be seen from the above my principal research aim is to analyse the interactions between cells
of the immune system and the blood ocular barriers. The elucidation of these mechanisms would
undoubtedly provide novel therapeutic modalities that could prevent disease itself or relapse. . I intend
to expand this work significantly in the future especially in the genomic field. Over the next 5 years I
also intend to undertake studies relating to the functional evaluation of genes shown as “hot spots”
from the recent WGAS in Behcet’s disease, to continue work on HLA, MICA and NKG2D interctions
with a particular emphasis on KIR polymorphisms and to confirm the genetic influences through family
studies.
Other research
I currently chair the British Ophthalmological Surveillance Unit, an active case reporting system
involving ophthalmologists throughout the UK for the ascertainment of rare ophthalmological
disorders. This system has been used to great success in other fields such as paediatric medicine and
we have currently just completed the first eleven years of operation where ophthalmological
surveillance is proving as useful. The findings of studies run through the Unit have been used to
inform national guidelines and patient consent, and have also provided data important to the public
health. In addition, I am involved in collaborative projects with researchers into diabetes. These
projects include the abnormal handling of glucose in patients on immunosuppression (with Professor
S Amiel, Diabetic Medicine, King’s College Hospital) and the relationship of polymorphisms in the
ACE gene with respect to the diagnostic evaluation of patients with sarcoidosis. I shall also shortly be
starting a study of the incidence and therapy of depression in the newly blind in conjunction with
researchers from the University of Cardiff.
TEACHING
Throughout my career I have been involved in teaching at both undergraduate and postgraduate
levels. On the clinical side this has involved regular lectures to non-specialist, theatre training and eye
training nurses. In addition I regularly carry out undergraduate and postgraduate teaching and
organise the regular postgraduate meetings held in the ophthalmology department as well as
contributing to and occasionally chairing the Medical Eye Unit grand round. I have also been a clinical
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page5 / 26
Curriculum vitae
Miles Stanford
examiner for the Final MB BS examinations. I have run an SSM in intraocular inflammation (12 week
course encompassing tutorials, clinic sessions, library essay and oral presentation) for 4th year
medical students at KCL for 6 years
At the national level I also contribute to postgraduate meetings (see below - Presentations).On the
academic side I have supervised and taught both intercalated BSc and MSc students in ocular
immunology. I have also been a co-supervisor to Clinical Research Fellows and currently supervise
the following:
PhD:
Ms Seema Shafi - The influence of MICA allelic forms on the activation status of immune cells in
Behcet’s disease
MD
Ms L Pelosini The clinical value of optical coherence tomography in cystoid macular oedema
Ms S Ahmadi-Lari. The role of macular pigment in age related macular degeneration
Mr A Barsom Corneal ectasia
Mr A Dhital Near vision function following cataract surgery
Mr R Petrarca Epimacular brachytherapy in the treatment of wet macular degeneration
Publications
THESES
1. Stanford MR. Investigation of early pathological changes in experimental allergic uveitis (EAU):
MSc Thesis, University of London, 1986
2. Stanford MR. Investigation of immunological mechanisms in experimental and human autoimmune
uveoretinitis. MD Thesis. Cambridge. 1994
CONTRIBUTIONS TO BOOKS
1. Kasp E, Graham EM, Stanford MR, Sanders MD, Dumonde DC. Retinal autoimmunity and
circulating immune complexes in Behçet's disease. In: Recent Advances in Behçet's Disease. Ed. T
Lehner, C G Barnes. 1985. RSM publications.
2. Stanford MR, Brown EC, Kasp E, Graham EM, Sanders Dumonde DC. A model of retinal vasculitis
in Man. Clinical and histological features of focal lesions found in experimental posterior uveitis in
black-hooded Lister rats. In: 4th International Congress of Immunology and Immunopathology of the
Eye. Ed. M Secchi. Padua, Italy. May 1986. Masson Press, Paris.
3. Banga J, Suleyman S, Stanford MR, Graham E, Brown EC, Kasp E, Sanders MD, Dumonde DC.
Restrictions in the autoantibody responses to distinct epitopes of retinal S-antigen in Man. In: 4th
International Symposium on the Immunology and Immunopathology of the Eye. Ed. M Secchi. Padua,
Italy. May 1986. Masson Press, Paris.
4. Stanford MR, Robbins J, Kasp E, Suleyman S and Dumonde DC. Electro-retinographic studies in
experimental allergic uveitis. In: Ophthalmology Today. Ed. Ferraz de Oliveiera. Excerpta Medica,
Amsterdam. 1988:pp21-26.
5. Graham E, Kasp E, Stanford MR, Sanders MD, Dumonde DC. Clinical and immunological features
of 150 patients with retinal vasculitis. In: World Uveitis Symposium. Eds. Belfort R, Petrilli A,
Nussenblatt R. Livrarian Roca Ltda, San Paulo, Brazil. 1989:p451
6. Edelsten C, Stanford MR, Graham EM. Evaluation of systemic immunosuppression in birdshot
retinochoroidopathy. In: Recent Advances in Uveitis. Dernouchamps J, Verongstroebe C, CaspersVelu L and Tassignan MJ (eds). (1993) Karger Publications, Amsterdam, pp497-500
7. Graham EM, Edelsten CE, Palmer H, Stanford MR, Sanders MD. Systemic morbidity of patients
present with isolated idiopathic retinal vasculitis. In: Advances in Ocular Immunology. Eds.
Nussenblatt RB, Whitcup SM, Caspi RR, Gery I. Elsevier Science BV, Amsterdam. pp331-334, 1994
8. Ellis BA, Stanford MR, Graham EM, Wallace GR. Immunoglobulin isotype usage in retinal
vasculitis. In: Advances in Ocular Immunology. Eds. Nussenblatt RB, Whitcup SM, Caspi RR, Gery I.
Elsevier Science BV, Amsterdam, pp323-327, 1994
9. Lehner T, Childerstone A, Perrin K, Hasan A, Direskenelli H, Stanford MR, Whiston R, Kasp E,
Dumonde DC, Shimmick T, van der Zee R, Miyushima Y. Stress proteins in Behçet's disease and
experimental uveitis. In: Stress Proteins in Medicine. Eds. van Eden W, Young DB. Marcel Decker Inc.
New York: 1995;pp163-186.
10. Graham EM, Stanford MR, Whitcup SM. Retinal vasculitis. In: Ocular Infection and Immunity. Eds.
Pepose J, Holland G, Wilhelmuis K. Mosby Year Book Inc. St Louis: 1996;pp538-552.
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page6 / 26
Curriculum vitae
Miles Stanford
11. Stanford MR. The current management of posterior segment inflammatory disease. Current
Medical Literature (Ophthalmology). 1996;5:99-102.
12. Stanford MR. The role of heat shock proteins in uveitis and Behçet’s disease. In: Uveitis Today.
Eds. Ohno S, Aoki K, Usui M, Uchio E. Elsevier Science BV Amsterdam: 1998;pp3-6
13. Uchio E, Stanford M, Hosan A, Ohno S, Lehner T. Humoral immune response in heat shock
protein (HSP)-induced rat uveitis. In: Uveitis Today. Eds. Ohno S, Aoki K, Usui M, Uchio E. Elsevier
Science BV Amsterdam. 1998;pp61-64
14. Kanawati CA, Verity DH, Holland-Gladwish J, Stanford MR. Cyclosporine in the management of
Palestinian patients with Behçet’s disease. In: Uveitis Today. Eds. Ohno S, Aoki K, Usui M, Uchio E.
Elsevier Science BV Amsterdam. 1998;pp145-150
15. Verity D, Stanford M, Vaughan R, Kondeatis E, Thuran J, Seed P, Kanwati C, Mann J, Madonat W,
Faysal F, Zureikat H, Wallace G. The role of tumour necrosis factor  (TNF) in ocular Behçet’s
disease (BD). In: Uveitis Today. Eds. Ohno S, Aoki K, Usui M, Uchio E. Elsevier Science BV
Amsterdam. 1998;pp165-166
16. Verity D, Madanat W, Kanawati C, Mann J, Faysal F, Zureikat H, Seed PT, Ayesh I, Stanford M.
Visual morbidity in Palestinian and Jordanian patients with ocular Behçet’s disease (BD). In: Uveitis
Today. Eds. Ohno S, Aoki K, Usui M, Uchio E. Elsevier Science BV Amsterdam. 1998;pp167-168.
17. Stanford MR. Multiple sclerosis. (CME) Ophthalmology 1998;2:86-88
18. Graham EM, Stanford MR. Retinal vasculitis and systemic disease. In: Oxford Textbook of
Ophthalmology. Eds. Sparrow J, Easty D. OUP. 1999. pp545-552.
19. Stanford MR, Gilbert RE. Epidemiology of ocular toxoplasmosis. In: Toxoplasmosis. Eds.
Petersen E, Ambroise-Thomas P. Springer Verlag, Copenhagen. 1999. Pp251-260.
20. Subak-Sharpe I, Stanford MR. The role of diagnostic tests in the management of patients with
uveitis. CME Journal (Ophthalmology) 2000;4:39-43.
21. Stanford MR Intraocular inflammation. In: Atlas of Clinical Ophthalmology. 3rd edition Eds Spalton
D Hitchings R Hunter PA. Gower Medical Publishing, London. 2004 pp
22. Aristodemou P, Stanford MR. The assessment of acute anterior uveitis in primary care. Clinical
Focus Primary Care. Rila Publications Ltd. 2005 1:40-3
23. Stanford MR. Endophthalmitis: diagnosis and management. Eds Peyman GA, Lee PJ, Seal DV.
Book Review. Eye 2006 20:632
24. Stanford MR, Barathan V Uveitis due to infective causes Eye News 2006 13;8-16
25. Stanford MR, Mathew R. Patterns of retinal vascular involvement in the diagnosis of retinal
vacuities. In: Uveitis and Immunological disorders Progress III Eds Pleyer U, Forrester JV. Springer
Verlag Berlin 2009 p87-95 (ISBN 978-3-540-69458-8)
26. Hughes E, Stanford MR. Medical Ophthalmology. In: Training in Ophthalmology. Eds Sundaran V,
Barsam A, Alwitry A, Khaw PT. Oxford University Press. Oxford 2009 pp193-236. (ISBN 978-0-19923759-3)
27. Pringle E, Stanford M. Ophthalmological Emergencies in rheumatic and autoimmune diseases. In
Autoimmune diseases: Acute and complex situations. Eds Khamashta MA, Ramos-Casals M.
Springer-Verlag London. 2011 pp291-314. (ISBN 978-0-85729-357-2.
28. Bye L, Modi N, Stanford M. Basic Sciences for Ophthalmology. Oxford University Press. Oxford.
2013 ISBN 978-0-19-958499-4
29. Petrushkin H, Stanford MR The Eye. In: Oxford Textbook of Rheumatology. Eds:Watts RA,
Conaghan PG, Denton C, Foster H, Isaacs J, Muller-Ladner U. Oxford University Press. Oxford 2013.
ISBN-978-0-19-962448-9
30. Jones-Odeh E, Lim KS, Stanford MR. Cytomegalovirusretinitis postintravitreal triamcinolone in an
immunocompetent patient with juvenile glaucoma. Eye News 2014 Dec/Jan p26
PEER-REVIEWED PAPERS
1. Leonard T, Graham E, Stanford MR, Sanders MD. Graves disease presenting with bilateral acute
painful proptosis, ptosis, ophthalmoplegia and visual loss. Lancet 1984;ii:431-433
2. Stanford MR. Retinopathy after irradiation and hyperbaric oxygen.
J Roy Soc Med 1984;1041-1043
3. Stanford MR, Chignell AH. Surgical treatment of superior bullous rhegmatogenous retinal
detachments. Br J Ophth 1985;69:729-732
4. Dumonde DC, Kasp E, Banga JP, Sanders MD, Graham E, Stanford MR et al Autoimmune
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page7 / 26
Curriculum vitae
Miles Stanford
mechanisms in inflammatory eye disease. Trans OSUK 1985; 104:232-238
5. Dewhirst R, Stanford MR. Retinal photography and fluorescein angiography in pigmented rats. Am
J Ophthal Photography 1986;9:10-12
6. Stanford MR, Brown EC, Kasp E, Graham EM, Sanders MD, Dumonde DC. Experimental posterior
uveitis I: A clinical angiographic and pathological study. Br J Ophthalmol 1987;71:585-592
7. Stanford MR, Graham E, Kasp E, Brown EC, Dumond DC, Sanders MD. Retinal vasculitis:
correlation of anaimal and human disease. Eye 1987;1:69-77
8. Graham EM, Stanford MR, Shilling JS, Sanders MD. Neovascularization in posterior uveitis. Br J
Ophthal 1987;71:826-833
9. Stanford MR, Graham E, Kasp E, Sanders MD, Dumonde DC. Modulation of experimental retinal
vasculitis using dexamethasone, cyclosporin A and prazosin. Eye 1987;1:626-631
10. Stanford MR, Kasp E, Brown EC, Graham E, Dumonde DC, Sanders MD. Differential effect of
Bordetella pertussis on experimental posterior uveitis in the black hooded Lister rat. Archives of
Ophthalmology 1988;196:111-114
11. Stanford MR, Graham EM, Kasp E, Sanders MD, Dumonde DC. A longitudinal study of clinical
and immunological findings in fifty-two patients with retinal vasculitis. Br J Ophthal 1988;72:442-447
12. Stanford MR, Robbins J. Experimental posterior uveitis II: Electro-retinographic findings. Br J
Ophthal 1988;72:88-96
13. Graham EM, Stanford MR, Sanders MD, Kasp E, Dumonde DC. A point prevalence study of 150
patients with idiopathic retinal vasculitis. Br J Ophthal 1989;73:714-721
14. Kasp E, Graham EM, Stanford MR, Sanders MD, Dumonde DC. A point prevalence study of 150
patients with idopathic retinal vasculitis. 2. Clinical relevance of antiretinal autoimmunity and circulating
immune complexes. Br J Ophth 1989;73:722-730
15. Stanford MR, Pappasavvas G, Berry HE. The red eye in rheumatology - diagnostic insights.
Rheumatology Today 1990;2:15-17
16. Stanford MR, Graham E. The eye in systemic inflammatory disease. Brit J Hosp Med
1990;44:100-105
17. Stanford MR, Graham E. Systemic associations of retinal vasculitis. Int Ophth Clin 1991;31:23-35
18. Kasp E, Stanford MR, Brown E, Coombes AGA, Dumonde DC. Circulating immune complexes
may play a regulatory and pathogenic role in experimental autoimmune uveoretinitis. Clin Exp
Immunol 1992;88:307-312
19. Stanford MR, Robbins J, Kasp E, Dumonde DC. Passive administration of antibody against retinal
S-antigen induces electroretinographic supernormality. Invest Ophth Vis Sci 1992;33:30-35
20. Roberts AJ, Kasp E, Stanford M, Dumonde DC, Banga JP. Induction of experimental autoimmune
uveoretinitis in Lewis rats with purified recombinant human retinal S-antigen fusion protein. Eur J
Immunol 1992;22:951-956
21. Edelsten CE, Stanford MR, Ormerod I, Welsh K, Graham EM. HLA-B7 in patients with retinal
vasculitis may predict the development of multiple sclerosis. Lancet 1992;339:942
22. Kasp E, Whiston R, Dumonde DC, Graham E, Stanford MR, Sanders MD. Antibody affinity to
retinal S-antigen in patients with retinal vasculitis. Am J Ophthalmol 1992;113:697-701
23. Kasp E, Roberts AJ, Stanford MR, Whiston R, Dumonde DC, Banga JP. Pathogenicity and
immunogenicity of recombinant human retinal S-antigen fusion protein. Curr Eye Res 1992;11:113118
24. Franks WA, Limb GA, Stanford MR, Ogilvie J, Wolstencroft R, Chignell AH, Dumonde DC.
Cytokines in human intraocular inflammation. Curr Eye Res 1992;11:187-192
25. Stanford MR, Fenech T, Hunter PA. Timing of removal of sutures in control of post-operative
astigmatism. Eye 1993;7:143-147
26. Bentley CP, Stanford MR, Shilling JS, Sanders MD, Graham EM. Macular ischaemia in posterior
uveitis. Eye 1993;7:411-414
27. Zaman AG, Edelsten C, Stanford MR, Graham EM, Ellis BA, Direskeneli H, De Cruz DP, Hughes
GRV, Dumonde DC, Wallace GR. Soluble inter-cellular adhesion molecule 1 (sICAM 1) as a marker of
disease relapse in idiopathic uveoretinits. Clin Exp Immunol 1994;95:60-65
28. Edelsten C, Stanford MR, Graham EM. Serpiginous choroiditis: an unusual presentation of ocular
sarcoidosis. Br J Ophthalmol 1994;78:70-72
29. Howe L, Stanford MR, Edelsten C, Graham EM. The efficacy of systemic corticosteroids in sight
threatening retinal vasculitis. Eye 1994;8:443-447
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page8 / 26
Curriculum vitae
Miles Stanford
30. Hunt BJ, Palmer HE, Jurd KM, Zaman AG, Stanford MR, Sanders MD, Graham EM.
Thrombophilia in isolated idiopathic retinal vasculitis. Lancet 1994;344:540
31. Stanford MR, Kasp E, Whiston R, Hasan A, Todryk S, Shimmick T, Mizushima Y, Dumonde DC,
van der Zee R, Lehner T. Heat shock protein peptides reactive in Behçet's disease are uveitogenic in
Lewis rats. Clin Exp Immunol 1994;97:226-231
32. Ellis BA, Patel SY, Stanford MR, Zaman AG, Graham EM, Wallace GR. Tumour necrosis factor
production by lipopolysaccharide-stimulated peripheral blood mononuclear cells from patients with
retinal vasculitis. Regional Immunol 1995;6:27-30
33. Palmer HE, Jurd KM, Hunt BJ, Zaman AG, Stanford MR, Sanders MD, Graham EM.
Thrombophilic factors in ischaemic and non-ischaemic idiopathic retinal vasculitis. Eye 1995;9:507512
34. Palmer HE, Zaman AG, Edelsten CE, Stanford MR, Graham EM. Systemic morbidity in patients
with isolated idiopathic retinal vasculitis. Lancet 1995;346:505-506
35. Gilbert RE, Stanford MR, Jackson H, Holliman RE, Sanders MD. Incidence of symptomatic
toxoplasma retinochoroiditis in South London according to country of birth. BMJ 1995;310:1037-1040
36. Stanford MR, Brooks CI, Edelsten CE, Hughes JD, Mitchell D, Sheppard MN, Sanders MD.
Paraneoplastic retinopathy in association with large cell neuroendocrine bronchial carcinoma. Br J
Ophthalmol 1995;79:617-620
37. Woon WH, Stanford MR, Graham EM. Severe idiopathic posterior scleritis in children. Eye
1995;9:570-574
38. Johnson R, Stanford MR, Verma S, Green WT, Graham EM. Resolution of calcific band
keratopathy after lowering elevated serum calcium in a patient with sarcoidosis. Br J Ophthalmol
1995;79:1050-1056
39. Stanford MR. Acute symptomatic toxoplasma retinochoroiditis. Eye 1996;10:3-4.
40. Direskeneli H, Hasan A, Shimmick T, Mizushima Y, van der Zee R, Fortune F, Stanford MR,
Lehner T. Recognition of B-cell epitopes of the 65 kDa HSP in Behçet's disease. Scand J Immunol
1996;43:464-471.
41. Hasan A, Fortune F, Wilson A, Warr K, Shimmick T, Mizushima Y, van der Zee R, Stanford MR,
Sanderson J, Lehner T. T cell receptor gd+ lymphocyte responses to peptides derived from stress
proteins in the pathogenesis and diagnosis of Behçet's disease. Lancet 1996;347:789-794.
42. Ellis BA, Almahdi N, Stanford MR, Morgan G, Wallace GR. Limitations of SCID-Hu mouse model
for antiretinal autoantibody responses. Ocular Immunol Inflamm 1996;4:125-128.
43. Palmer HE, Stanford MR, Sanders MD, Graham EM. Visual outcome of patients with idiopathic
ischaemic and non-ischaemic retinal vasculitis. Eye 1996;10:343-348.
44. Palmer HE, Zaman AG, Ellis BA, Stanford MR, Graham EM, Wallace GR. Longitudinal analysis of
soluble intercellular adhesion molecule-1 in retinal vasculitis patients. Eur J Clin Invest 1996;26:686691.
45. Howe LJ, Stanford MR, Whiston R, Dewhirst R, Marshall J. Angiographic abnormalities of
experimental autoimmune uveitis. Curr Eye Res 1996;15:1149-1155.
46. Cordeiro F, Phillips P, Stanford MR, Shilling JS. Outcome of laser photocoagulation for proliferative
diabetic retinopathy in relation to other systemic microvascular complications.
Eye 1997;11:531-536
47. Howe LJ, Stanford MR, Graham EM, Marshall J. Indocyanine green (ICG) angiography in patients
with birdshot retinochoroiditis. Eye 1997;11:554-559
48. Stanford MR. Tolerance: will it end in tears? Eye 1997;11:441-442
49. Stanford MR. A British Ophthalmological Surveillance Unit. Br J Ophthalmol 1997;81:932-933
50. Limb GA, Early O, Hollifield R, Russell W, Stanford MR. Expression of haematopoietic cell
markers by retinal pigment epithelial cells. Curr Eye Res 1997;16:985-991
51. Palmer HE, Stanford MR, Graham EM. Non-caseating granulomas as a cause of ischaemic
retinal vasculitis. Br J Ophthalmol 1997;81:1018-1019
52. Hill TA, Stanford MR, Graham EM, Dumonde DC, Brown KA. A new method for studying the
selective adherence of blood lymphocytes to the microvasculature of human retina. Invest Ophth Vis
Sci 1997;38:2608-2613
53. Verity DH, Wallace GR, Seed PT, Kanawati CA, Ayesh I, Holland-Gladwish J, Stanford MR.
Soluble adhesion molecules in Behçet’s disease. Ocular Immunol Inflamm 1998:6:81-92
54. Jackson H, Stanford MR. Fluorescein angiography in posterior uveitis. Br J Ophthal Photog.
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page9 / 26
Curriculum vitae
Miles Stanford
1998;1:4-11
55. Hu W, Hosan A, Wilson A, Stanford MR, Li-Yang Y, Todryk S, Whiston R, Shinnick T, Miyushima Y,
van der Zee R, Lehner T. Experimental mucosal induction of uveitis with the 60 kD HSP-derived
peptide aa336-351. Eur J Immunol. 1998;28:2444-2455
56. Whittle RM, Wallace GR, Whiston RA, Dumonde DC, Stanford MR. Human anti-retinal antibodies
in toxoplasma retinochoroiditis. Br J Ophthalmol. 1998;82:1017-1021
57. Howe L, Stanford MR, Graham EM, Marshall J. Indocyanine green angiography in choroidal
inflammation. Eye. 1998;12:761-767
58. Parnaby-Price A, Stanford MR, Biggerstaff J, Howe L, Whiston RA, Marshall J, Wallace GR.
Leucocyte trafficking in experimental autoimmune uveitis in vivo. J Leucocyte Biol. 1998;64:434-440
59. Greenwood J, Stanford MR, Graham EM. Azathioprine in the management of retinal vasculitis.
Eye. 1998;12:783-788
60. Hammond CJ, Chauhan DS, Stanford MR. Primary pulmonary hypertension and diffuse macular
oedema responsive to acetazolamide. Arch Ophthalmol.1998;116:1535-1536
61. Kidd D, Plant G, Stanford MR, Scaravelli F, McCartney A, Graham EM. Metastatic
chorioncarcinoma presenting as multiple intracerebral haemorrhages: the role of imaging in the
elucidation of pathology. JNNP 1998;65:939-941
62. Greenwood J, Hughes J, Wallace GR, Seed P, Stanford MR, Graham EM. Soluble intercellular
adhesion molecule-1 (sICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in patients with
HIV/AIDS does not appear to correlate with CMV retinitis. Int J Std Aids 1998;1(11):713-714
63. Uchio E, Stanford M, Hasan A, Satoh S, Ohno S, Shimmick T, van der Zee R, Mizushima Y,
Lehner T. HSP-derived peptides inducing uveitis and IgG and IgA antibodies. Exp Eye Res
1998;67:719-727
64. Bremner F, Stanford MR, Sanders MD. Gaze evoked amaurosis in dysthyroid eye disease. Br J
Ophthalmol 1999;83:501
65. Cook H, Stanford MR, Long V, Newsom R, Smith S, Shilling JS, Marshall J. Natural history of
minimal macular exudates in diabetic retinopathy. Br J Ophthalmol 1999;83:563-566.
66. Dewhirst RR, Stanford MR. Severe adverse reactions to sodium fluorescein. Br J Ophth Photog
1999;2:20-21.
67. Wallace GR, Verity DH, Delamaine LJ, Ohno S, Inoko H, Ota M, Mizuki N, Yabuki K, KondiatisE,
Stephens HAF, Madanat W, Kanawati CA, Stanford MR, Vaughan RW. MICA allele profiles and HLA
Class I associations in Behçet’s disease. Immunogenetics 1999;49:613-617.
68. Verity DH, Marr JE, Wallace GR, Stanford MR. Behçet’s disease, the Silk Road and HLA B51:
historical and geographical perspectives. Tissue Antigens 1999;54:213-220..
69. Verity DH, Wallace G, Vaughan R, Ohno S, Kondeatis E, Madanat W, Fayyad F, Marr J,
Stanford M. HLA and TNF polymorphisms in ocular Behçet’s disease. Tissue Antigens 1999;54:264272.
70. Verity DH, Vaughan RW, Madanat W, Kondeatis F, Zaireikat H, Fayyad F, Kanawati C, Ayesh I,
Stanford MR, Wallace GR. Factor V Leiden mutation is associated with ocular involvement in Behçet’s
disease. Am J Ophthalmol 1999;128:352-356.
71. Gilbert RE, Dunn DT, Lightman S, Murray PI, Pavesio CE, Gormley PD, Masters J, Parker SP,
Stanford MR. Incidence of symptomatic toxoplasma eye disease: aetiology and public health
implications. Epidem Infect 1999;123:283-289.
72. Wallace GR, Whiston RA, Stanford MR, Wells GMA, Gearing AJH, Clements JM. The matrix
metalloproteinase inhibitor, BB-1101, prevents experimental autoimmune uveoretinitis. Clin Exp
Immunol 1999;118:364-370.
73. Palmer HE, Stanford MR, Lowy C, Wheeler MJ, Wallace GR, Graham EM. The pituitary-adrenal
axis in idiopathic retinal vasculitis. Br J Ophthalmol 1999;83:1393-95.
74. Cook HL, Stanford MR, Marshall J. Reference standards in diabetic retinopathy screening: which
method is best? Lasers Light 1999;9:15-27.
75 Edelsten C, Pearson A, Joynes E, Stanford MR, Graham EM. The ocular and systemic prognosis
of patients presenting with sarcoid uveitis. Eye 1999;13:748-753.
76. Brunton CL, Wallace GR, Graham EM, Stanford MR. The effect of cytokines on the replication of
T.gondii within rat retinal vascular endothelial cells. J Neuroimmunol 2000;102:182-188.
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page10 / 26
Curriculum vitae
Miles Stanford
77. Gilbert RE, Stanford MR. Is ocular toxoplasmosis due to prenatal or postnatal infection? Br J
Ophthalmol 2000;84:224-226.
78. Meacock W, Stanford MR, Spalton DJ. Cytokines in posterior capsule opacification. Br J
Ophthalmol 2000;84:332-336.
79. Antcliffe RJ, Stanford MR, Chauhan DS, Graham EM, Spalton DJ, Shilling JS, ffytche TJ, Marshall
J. Comparison between optical coherence tomography and fundus fluorescein angiography for the
detection of cystoid macular oedema in patients with uveitis. Ophthalmology 2000;107:593-599.
80. Verity DH, Vaughan RW, Kondeatis E, Madanat W, Zureikat H, Fayyad F, Marr JE, Kanawati Ca,
Wallace GR, Stanford MR. Intercellular adhesion molecule-1 gene polymorphisms in Behçet’s
disease. Eur J Immunogenet 2000;27:73-76.
81. Verity D, Stanford MR. Diagnosis and management of retinal vasculitis. Int Ophth Clin 2000;40:6984.
82. Cook HL, Heacock GL, Stanford MR, Marshall J. Detection of retinal lesions after telemedicine
transmission of digital images. Eye 2000;14:563-571.
83. Verity DH, Graham EM, Carr R, van der Walt JD, Stanford MR. Hypopyon uveitis and iris nodules
in non-Hodgkin'’ lymphoma: ocular relapse during systemic remission. J Clin Oncol 2000;12:292-294.
84. Palmer H, Giovanna G, Stanford MR, Wallace GR, Graham EM. Urinary neopterin as a marker for
disease activity in retinal vasculitis. Br J Ophthalmol 2001;85:30-33..
85. Mizuki N, Yabutzi K, Ota M, Verity D, Katsuyama Y, Ando H, Omari K, Goto K, Imagwa Y, Madanet
W, Fayyad F, Stanford M, Ohno S, Inoko H. Microsatellite mapping of a susceptible locus within the
HLA region for Behçet's disease using Jordanian patients. Hum Immunol 2001;62:186-90.
86. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, ffytche TJ, Marshall J. Intravitreal triamcinolone
for uveitic cystoid macula oedema: an optical coherence tomography study. Ophthalmology
2001;108:765-72.
87. Noury AMS, Bailey CC, Stanford MR, Graham EM. Blood-stained keratic precipitates: presenting
feature of sarcoidosis with thrombocytopaenia. Eye 2001;15:241-2.
88. Chak M, Wallace GR, Graham EM, Stanford MR. Thrombophilia: genetic polymorphisms and their
association with retinal vascular disease. Br J Ophthalmol 2001;85:883-6.
89. Rahi J, Stanford MR. Treatment of amblyopic eyes. Lancet (Letter) 2001;357:p1888.
90. Gilbert RE, See SE, Jones LV, Stanford MR. Antibiotics for toxoplasma retinochoroiditis (Cochrane
review). In: The Cochrane Library. Issue 5, 2002. Oxford. Update Software.
91. Tan JCH, Byles D, Stanford MR, Frith PA, Graham EM. Acute retinal necrosis in children caused
by herpes simplex virus. Retina 2001;21:344-7.
92. Noury AMS, Stanford MR, Graham EM. Radioiodine and Graves’ ophthalmopathy reconsidered.
Nuclear Med Comm 2001;22:1167-9.
93. Foot BG, Stanford MR. Questioning questionnaires. Eye 2001;15:693-4.
94. Stanford MR, Gras L, Wade A, Gilbert RE. Reliability of expert interpretation of retinal photographs
in the diagnosis of toxoplasma retinochoroiditis. Br J Ophthalmol 2002;86:636-40
95. Stanford MR. Five years of surveillance: The British Ophthalmological Surveillance Unit. Br J
Ophthalmol 2002;86:838-9
96. Jones NP, Anderton LC, Cheong FM, Whallet A, Stanford MR, Murray PI, Lesnik-Oberstein S,
Pavesio C. Corticosteroid-induced osteoporosis in patients with uveitis. Eye 2002;16:587-593
97. Chak M, Stanford MR, Poon W, Graham EM, Tungekar MF, Goldsmith D. Uveitis initiating an
autoimmune reaction resulting in Goodpasture’s syndrome. Br J Ophthalmol 2002;86:1188-90
98. Foot B, Stanford MR, Rahi J, Thompson J. The British Ophthalmological Surveillance Unit: An
evaluation of the first three years. Eye 2003;17:9-15
99. Phipps PA, Stanford MR, Sun JB, XiaoBG, Holmgren J, Shinnick T, Hasan A, Mizushima Y,
Lehner T. Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera
toxin B subunit. Eur J Immunol 2003;33:224-32
100. Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-Hawes K, Armuzzi A, Crawshaw
J, Fortune F, Walton R, Stanford MR, Welsh KI, Marshall SE, Jewell DP. Mapping the HLA association
in Behcet’s disease: A role for tumour necrosis factor polymorphisms? Arthritis Rheum. 2003;48:80713
101. Stanford MR. Behcet’s Syndrome: New treatments for an old disease. Br J Ophthalmol.
2003;87:381-2
102. Francis PJ, Jackson H, Stanford MR, Graham EM. Inflammatory optic neuropathy as the
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page11 / 26
Curriculum vitae
Miles Stanford
presenting feature of herpes simplex acute retinal necrosis. Br J Ophthalmol. 2003;87:512-4
103 Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with paediatric uveitis
in English primary and referral centres. Am J Ophthalmol 2003; 135:676-80
104 Stanford MR, See SE, Jones LV, Gilbert RE. Antibiotics for toxoplasmic retinochoroiditis. An
evidence-based systematic review. Ophthalmology 2003;110:926-32
105 Poon W, Verity DH, Larkin GL, Graham EM, Stanford MR. Behcet’s disease in patients of West
African and Afro-Caribbean Origin. Br J Ophthalmol 2003;87:876-8
106 Jackson TL, Eykyn SJ, Graham EM, Stanford MR Endogenous bacterial endophthalmitis: A 17
year prospective series and review of 268 reported cases. Surv Ophthalmol 2003;48:403-23
107 Chen Y, Vaughan RW, Kondeatis E, Fortune F, Stanford MR, Wallace GR. Factor V Leiden
mutation does not correlate with retinal vascular occlusion in Caucasian patients with Behcet’s
disease. Br J Ophthalmol 2003;87:1048-9
108 Verity DH, Wallace GR, Vaughan RW, Stanford MR. Behcet’s disease;from Hippocrates to the
third millenium. Br J Ophthalmol 2003;87:1175-83
109 Francis PJ, Stanford MR, Graham EM. Dehydration as a risk factor for central retinal vein
occlusion in young patients. Acta Ophthalmol Scand 2003; 81:415-6
110 Strouthidis N, Francis PJ, Holder GE, Stanford MR, Bird AC, Graham EM. Posterior segment
complications of graft versus host disease after bone marrow transplantation. Br J Ophthalmol
2003;87:1421-3
111 Lehner T, Stanford MR, Phipps PA, Sun JB, XiaoBG, Holmgren J, Hasan A, Mizushima Y.
Immunopathogenesis and prevention of uveitis with the Behcet’s disease specific peptide linked to
cholera toxin B. Adv Exp Med Biol 2003;528:173-80
112 Wallace GR, Farmer I, Church A, Graham EM, Stanford MR. Serum levels of chemokines
correlate with disease activity in patients with retinal vasculitis. Immunol Lett 2003;90:59-64
113 Chen Y, Vaughan RW, Kondeatis E, Fortune F, Graham EM, Stanford MR, Wallace GR. CCL2
and CCL5 gene polymorphisms associate with gender in patients with Behcet’s disease. Tissue
Antigens 2004;63:41-45
114 Yang X, Ahmad T, Gogus F, Wallace GR, Madanat W, Kanawati CA, Stanford MR, Fortune F,
Jewell DP, Marshall SE. Analysis of the CC chemokine receptor 5 (CCR5) Delta32 polymorphism in
Behcet’s disease. Eur J Immunogenet 2004; 31:11-4
115 Stanford MR. The pathogenesis of diabetic retinopathy – sticky blood or sticky vessels? Br J
Ophthalmol 2004;88:444-5
116 Stanford MR, Whittall T, Bergmeister LA, Lindblad M, Lic SLP, Mizushima Y, Holmgren J, Lehner
T. Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in the treatment of uveitis in
Behcet’s disease. Clin Exp Immunol 2004;137:201-8
117 Jackson TL, Hillenkamp J, Knight BC, Zhang JJ, Thomas D, Stanford MR, Marshall J. Safety
testing of indocyanine green and trypan blue using retinal pigment epithelium and glial cell cultures.
Invest Ophth Vis Sci 2004;45:2778-85
118 Meacock WR, Spalton DJ, Bender L, Antcliff R, Heatley C, Stanford MR, Graham EM. Steroid
prophylaxis in eyes with uveitis undergoing phacoemulsification. Br J Ophthalmol 2004;88:1122-4
119 Jackson T, Vote B, Knight BC, El-Amir A, Stanford MR, Marshall J. Safety testing of infracyanine
green using retinal pigment epithelium and glial cell cultures. Invest Ophthalmol Vis Sci. 2004 ;
45:3697-703.
120 Knight BC, Modi NC, Brunton CL, Wallace GR, Stanford MR The effect of Toxoplasma gondii
infection on expression of chemokines in retinal vascular endothelial cells. J Neuroimmunol. 2005;
160:41-7
121 Rahi J, Stanford MR, Foot B. Underestimating the importance of amblyopia: flawed methodology.
A reply. Eye 2005;19:350-1
122 Moradi P, Roberton B, Osborne R, Muhtaseb M, Graham EM, Klein J, Stanford MR. HACEK
endocarditis causing endogenous endophthalmitis and a metastatic abscess. Eye. 2006;20:254-5
123 Stanford MR, Vaughan RW, Kondeatis E, Chen Y, Edelsten CE, Graham EM, Wallace GR. Are
cytokine gene polymorphisms associated with outcome in patients with idiopathic intermediate uveitis
in the United Kingdom? Br J Ophthalmol. 2005 ;89:1013-6.
124 Stanford MR, Tomlin E, Comyn O, Hollands K, Pavesio C. The visual field in toxoplasmic
retinochoroiditis. Br J Ophthalmol 2005;89:812-4
125 Minasian M, Stanford M, Graham E, Denton CP, Black C. Bilateral ischaemic retinal vasculopathy
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page12 / 26
Curriculum vitae
Miles Stanford
in scleroderma. Br J Ophthalmol. 2005; 89:1064-5.
126 Shah SP, Hadid OH, Graham EM, Stanford MR. Acute retinal necrosis presenting as central
retinal artery occlusion with cilioretinal sparing. Eur J Ophthalmol. 2005 ;15:287-8.
127 Holmgren J, Adamsson J, Anjuere F, Clemens J, Czerkinsky C, Eriksson K, Flach CF, GeorgeChandy A, Harandi AM, Lebens M, Lehner T, Lindblad M, Nygren E, Raghavan S, Sanchez J,
Stanford MR, Sun JB, Svennerholm AM, Tengvall S. Mucosal adjuvants and anti-infection and antiimmunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol
Lett. 2005;97:181-8.
128 Hadid OH, Shah SP, Sherafat H, Graham EM, Stanford MR. Streptococcus anginosus-associted
endogenous endophthalmitis mimicking fungal endophthalmitis. J Clin Microbiol 2005; 43:4275-6
129 Hughes EH, Collins RW, Kondeatis E, Wallace GR, Graham EM, Vaughan RW, Stanford MR.
Associations of major histocompatibility complex class I chain-related molecule polymorphisms with
Behcet’s disease in Caucasian patients. Tissue Antigens 2005;66:195-9
130 Angunawela RI, Heatley CJ , Williamson TH, Spalton DJ, Graham EM, Stanford MR Intravitreal
triamcinalone acetonide for refractory uveitic cystoid macular oedema: long term outcome Acta Scand
Ophthalmol 2005;83:595-9
131 Aristodemou P, Stanford MR. The assessment of acute anterior uveitis in primary care. Clinical
Focus:Primary Care. 2005;1:40-2
132 Rajan MS, Pantelidis P, Tong CYW, French GL, Graham EM, Stanford MR. Diagnosis of
Treponema pallidum in vitreous samples using real time PCR. Br J Ophthalmol 2006;90:647-8
133 Wallace GR, Vaughan RW, Kodeatis E, Mathew R, Chen Y, Graham EM, Stanford MR. A
CX3CR1 genotype associated with retinal vasculitis in UK patients. IOVS 2006;47:2966-70
134 Gilbert RE, Tan HK, Cliffe S, Guy E, Stanford MR. Symptomatic toxoplasmosis in childhood in the
United Kingdom. Arch Dis Child 2006;91:495-8
135 Stanford MR, Tan HK, Gilbert R. Toxoplasmic Retinochoroiditis presenting in childhood: Clinical
findings in a UK Survey.Br J Ophthalmol. 2006;90:1464-7
136 Aristodemou P, Stanford M. Therapy Insight: the recognition and treatment of retinal
manifestations of systemic vasculitis Nat Clin Pract Rheumatol 2006 2:443-51
137 Knight BC, Kissane S, Falciani F, Salmon M, Wallace GR, Stanford MR,. Expression analysis of
immunomodulatory genes of Muller cells infected with Toxoplasma gondii. J Neuroimmunol
2006:179:126-31
138 Soomro H, Armstrong M, Graham EM, Stanford MR. Sudden loss of vision caused by a vasculitic
ophthalmic artery occlusion in a patient with ankylosing spondylitis and Crohn’s disease. Br J
Ophthalmol 2006 90:1438
139 Hughes E, Stanford MR. Advances in the understanding of toxoplasma retinochoroiditis
Ophthalmol Int 2006 1:49-53
140 Melillo N, Sanglis S, Stanford MR, Andrews T, D’Cruz DP. Low-dose intravenous
cyclophosphamide therapy in a patient with neurological complications of Behcet’s disease. Clin
Rheumatol 2007 26:1365-7
141 Wallace GR, Kondeatis E, Vaughan RW, Verity DH, Chen Y, Fortune F, Madanat W, Kanawati
CA, Graham EM, Stanford MR. IL-10 genotype analysis in patients with Behcet’s disease. Hum
Immunol. 2007;68:122-7
142 Lewis KA, Graham EM, Stanford MR. Systematic review of ethnic variation in the phenotype of
Behcet’s disease: Scan J Rheumatol 2007: 36; 1-6
143 Sfikakis PP, Markomichelakis N , Alpsoy E , Assaad-Khalil S , Bodaghi B , Gul A , Ohno S ,
Pipitone N , Schirmer M , Stanford M , Wechsler B, Zouboulis C, Kaklamanis P, Yazici H Anti-TNF
therapy in the management of Behcet's Disease: Review and basis for recommendations
Rheumatology 2007:46;736-41
144 Tan HK, Schmidt D, Stanford M, Salt A, Wallon M, Freeman K, Gilbert RE*, for The European
Multicentre Study on Congenital Toxoplasmosis (EMSCOT)* Risk of visual impairment in children with
congenital toxoplasmic retinochoroiditis. Am J Ophthalmol 2007:144;648-53
145 Hu V, Zaidi F, Larkin M, Muir G, Stanford M. Bilateral endogenous endophthalmitis after holmium
laser lithotripsy. Urology 2007:70;590 e13-14
146 Kitaichi N, Miyazaki A, Stanford MR, Shams H, IwataD, Ohno S. Ocular features of Behcet’s
disease: an international collaborative study. Br J Ophthalmol 2007:91;1579-82
147 Baranathan V, Stanford MR, Vaughan RW, Kondeatis E, Graham EM, Fortune F, Madanat W,
Kanawati C, Al-Jouani A, Murray PI, Wallace GR. The association of the PTPN22W polymorphism
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page13 / 26
Curriculum vitae
Miles Stanford
with Behcet’s disease Ann Rheum Dis 2007:66;1531-3
148 Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kötter I, Olivieri
L, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stübiger N, Yurdakul S,Yazici H EULAR
Recommendations For The Management Of Behçet’s Disease: Report Of A Task Force Of The
European Standing Committee For International Clinical Studies Including Therapeutics (Escisit) Ann
Rheum Dis 2008 67;1656-62
149 Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kötter I, Olivieri
L, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stübiger N, Yurdakul S,Yazici H Management of
Behçet’s Disease: a Systematic Literature Review for the EULAR Evidence Based Recommendations
for the Management of Behçet’s Disease Ann Rheum Dis 2009:10;1528-34
150 Benard A, Petersen E, Salamon R, Chene G, Gilbert R, Salmi LR; European Toxo Prevention
Study group (EUROTOXO). Survey of European programmes for the epidemiological surveillance of
congenital toxoplasmosis. Euro Surveill 2008:13;18834
151 Freeman K, Tan HK, Prusa A, Petersen E, Buffalano W, Malm G, Cortina-Borha M, Gilbert R;
European multicentre study on toxoplasmosis. Predictors of retinochoroiditis in children with
congenital toxoplasmosis: European prospective cohort study. Paediatrics 2008: 121; 1215-22
152 Bye L, Modi N, Stanford MR, Kondeatis E, Vaughan RW, Fortune F, Kanawati C, Ben-Chetrit E,
Ghabra M, Murray PI, Wallace GR.CTLA-4 polymorphisms are not associated with ocular
inflammatory disease. Tissue Antigens 2008 72;49-53
153 Hughes EH, Petruskin H, Sibtain NA, Stanford MR, Plant GT, Graham EM. Tuberculous orbital
apex syndromes. Br J Ophthalmol 2008 92;1151-7
154 Wallace GR, Stanford M. Immunity and toxoplasma retinochoroiditis. Clin Exp Immunol 2008
153;309-15
155 Gilbert RE, Freeman K, Lago EG, Bahia-Oliveira LMG, Tan HK, Wallon M, Buffolano W, Stanford
MR, Petersen E for the European Multicentre study of congenital toxoplasmosis (EMSCOT) Ocular
sequelae of congenital toxoplasmosis in Brazil compared with Europe PloS Negl Trop Dis 2008
2;e277
156 Wallace, G R; Curnow J, Pryce K, Knight B, Modi N, Graham EM, Stewart J, Fortune F, Murray P
I, Stanford MR Serum Cytokine Profiles In Behçet’s Disease: A Role For IL-15? Immunol Lett 2008
121;7-12
157 Dodds EM, Holland GN, Stanford MR, Yu F, Siu WO, Shah KH, Ten-Dam van Loon N. Muccioli
C, Hovakimyan A, Barisani-Asenbauer T; International Ocular Toxoplasmosis Research Group.
Intraocular inflammation associated with ocular toxoplasmosis: relationships at initial examination. Am
J Ophthalmol 2008:146;856-65
158 Martin TM, Bye L, Modi N, Stanford MR, Vaughan R, Smith JR, Wade NK, Mackensen F, Suhler
EB, Rosenbaum JT, Wallace GR. Genotype analysis of polymorphisms in autoimmune susceptibility
genes CTLA4 and PTPN22 in an acute anterior uveitis cohort. Mol Vis 2009:15;208-12
159 Mumcu G, Niazi S, Stewart J, Hagi-Pavli E, Gokani B, Noha S, Ergun T, Stanford M, Fortune F,
Direskineli H. Oral health and related quality of life status in patients from the UK and Turkey: A
comparative study in Behcet’s disease. J Oral Pathol Med Epub Feb 2009
160 Stanford MR, Gilbert RE. Treating ocular toxoplasmosis – current evidence. Mem Inst Oswaldo
Cruz 2009: 104;312-5
161 Kitaichi N, Miyazaki A, Stanford MR, Iwata D, Chams H, Ohno S Low prevalence of juvenile
onset Behcet’s disease with uveitis in East/South Asian people. Br J Ophthalmol 2009:93;1428-30
162 Kappen J.H., Wallace G.R., Stolk L., F. Rivadeniera F., Uitterlinden A.G., van Daele P.L.A, Laman
J.D, Stanford M.R., Fortune F, Madanat W, van Hagen P.M, van Laar JAM Low prevalence of NOD2
SNPs in Behçet’s disease suggests protective association in Caucasians Rheumatology
2009:48;1375-7
163 Wong R, Pavesio CE, Laidlaw DAH, Williamson TH, Graham EM, Stanford MR. Acute retinal
necrosis: the effects of intravitreal foscarnet and virus type on visual outcome. Ophthalmology 2010
117;556-60
164 Wong RW, Gupta B, Stanford MR, Laidlaw DAH. Intravitreal Bevacizumab to facilitate vitrectomy
in idiopathic ischaemic retinal vasculitis. Int Ophthalmol 2010 30:415-9
165 Nanavaty MA, Stanford MR, Sharma R, Spalton DJ, Marshall J. Objective quantification of ocular
scatter in patients with uveitis. Ophthalmologica 2010 225:61-6
166 Padroni S, Pringle E, Stanford M. Pitfalls in visual field testing. Neuro-ophthalmol 2010 34:104-7
167 Pavameswaran A, Stanford M, Radovan S, Dearden CE. Ocular and cerebral aspergillosis in a
non-neutropenic patient following alemtuzumab and methyl prednisolone treatment for chronic
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page14 / 26
Curriculum vitae
Miles Stanford
lymphocytic leukaemia. J Infect Chemother 2010 16: 150-1
168 Pelosini L, Hull CC, Boyce JF, McHugh D, Stanford MR, Marshall J. Optical Coherence
Tomography may be used to predict Visual Acuity in Macular Oedema. Invest Ophth Vis Sci (E pub
Jun 2010)
169 Remmers EF, Cosan F, Kirino Y, Ombello MJ, Abaci N, Satorius C, Le JM, Yang B, Korman BD,
Cakiris A, Aglar O, Emrence Z, Azakli H, Ustek D, Turgal-Tutkan I, Akman-Demir G, Chen W, Amos
CI, Dizon MB, Kose AA, Azizlerli G, Erer B, Brand OJ, Kaklamani VG, Kaklamanis P, Ben-Chetrit E,
Stanford M, Fortune F, Ghabra M, Ollier WER, Cho Y-H, Bang D, O’Shea J, Wallace GR, Gadina M,
Kastner DL, Gul A. Genome-wide association study identifies variants in the MHC class 1, IL 10, and
IL23R-IL12RB2 regions associated with Behcet’s disease, Nat Genet 2010 42;698-702
170 Dhital A, Pey T Stanford MR. Vision loss and falls. Eye 2010 24:1437-46
171 Wong R, Graham EM, Stanford MR. Immune choroiditis following contralateral acute retinal
necrosis Arch Ophthalmol 2010 128:1364-6
172 Ramachandran R, Hughes E, Larkin G, Graham E, Stanford M, Lim M. Secondary frosted branch
angiitis in Neuro-Behcet’s disease with serous macular detachment. Paediatr Int 2011 53:285-6
t]
173 Macey M, Hagi-Pavli E, Stewart J, Wallace GR, Stanford M, Shirlaw P, Fortune F. Age,gender
and disease related platelet and neutrophil activation ex vivo in whole blood samples from patients
with Behcet’s disease. Rheumatology 2011 150:1849-59
174 Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Whitcup SM,
Ozurdex HURON Study Group.Dexamethasone intravitreal implant for non-infectious intermediate or
posterior uveitis Arch Ophthalmol. 2011 May;129(5):545-53.
175 Durrani O, Banahan K, Sheedy FJ, McBride L, Ben-Chetrit E, Greiner K, Vaughan RW, Kondeatis
E, Hamburger J, Fortune F, Stanford MR, Murray PI, O’Neill LA, Wallace Gr. TIRAP Ser180Leu
polymorphism is associated with Behcet’s disease. Rheumatology 2011 50:1760-5
177 De-la-Torre A, Stanford M, Curi A, Jaffe GJ, Gomez-Marin JE. Therapy for ocular toxoplasmosis
Ocul Immunol Inflamm 2011 19:214-20
178 Shunmugan M, Chan E, O’Brart D, Moonim MT, Stanford MR, Morley AM. Cutaneous gamma
delta T cell lymphoma presenting with ocular and adnexal features. Arch Ophthalmol 2011 129:137981
179 Shafi S, Vantourout P, Wallace G, Vaughan R, Stanford M, Hayday A. An NKG2D-mediated
human lymphoid stress-surveillance response with high inter-individual variation. Sci Transl Med. 2011
3: 113 ra124
180 Petersen E, Stanford MR, Kijilstra A. Epidemiology of ocular toxoplasmosis Ocul Inflam Immunol
2012 20:68-75
181 Author response: predictors of macular edema Pelosini L, Hull CC, Boyce JF, McHugh D,
Stanford MR, Marshall J. Invest Ophthalmol Vis Sci. 2012 53:924
182 Margrain TH, Nollett C, Shearn J, Tudor Edwards R, Ryan B, Bunce C, Castin R, Hegel M, Smith
DJ. The Depression in Visual Impairment Trial (DEPVIT): trial design and protocol. BMC Psychiatry
2012 12:57
183 Okada AA, Stanford MR, Tabbara K. Ocular Behcet’s Disease: Severity grading, diagnostic
criteria and ancilliary testing. Ocul Inflam Immunol 2012 20 387-93
184 Quax RAM, van Laar JAM, van Heerebeek, Greiner K, Ben-Chetrit E, Stanford M, Wallace GR,
Fortune F, Ghabra M, Soylu M, Hazes JMW, Lamberts SWJ, Kappen JH, van Hagen PM, Koper JW,
Feelders RA. Glucocorticoid sensitivity in Behcet’s disease. Endocrine Connections 2012 1:103-11
185 Koutroumanos N, Folkard A, Mattocks R, Wright J, Xing W, Wilson-Barrett C, Bonstein K,
Pavesio C, Westcott M, Moore G, Stanford M, Bunce C, Okhravi N. Bringing togrther patient and
specialists: The first Birdshot day. Br J Ophthalmol 2013 97:648-52
186 Garweg JG, Stanford MR. Therapy for ocular toxoplasmosis – the future. Ocul Immunol Inflamm
2013 21:300-5
187 Spectral domain optical coherence tomography findings in a case series of patients with bilateral
diffuse uveal melanocytic proliferation. Shalchi Z, Shunmugam M, Mahroo OA, McDonald RJ,
Dogramaci M, Laidlaw DA, Stanford M, Mohamed M.
Ocul Immunol Inflamm. 2014 Dec;22(6):490-3. doi: 10.3109/09273948.2014.926935.
188Pegylated interferon-α-2b reduces corticosteroid requirement in patients with Behçet's disease
with upregulation of circulating regulatory T cells and reduction of Th17 .Lightman S, Taylor SR, Bunce
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page15 / 26
Curriculum vitae
Miles Stanford
C, Longhurst H, Lynn W, Moots R, Stanford M, Tomkins-Netzer O, Yang D, Calder VL, Haskard DO.
Ann Rheum Dis. 2014 Sep 30. pii: annrheumdis-2014-205571. doi: 10.1136/annrheumdis-2014205571
189 Possession of the HLA-DRB1*1501 Allele and Visual Outcome in Idiopathic Intermediate Uveitis.
Petrushkin H, Thomas D, Vaughan R, Kondeatis E, Stanford MR, Edelsten C, Wallace GR JAMA
Ophthalmology Epub
190 Clinical Review: Familial Mediterranean Fever-An Overview of Pathogenesis, Symptoms, Ocular
Manifestations, and Treatment. Petrushkin H, Stanford M, Fortune F, Jawad AS.
Ocul Immunol Inflamm. 2015 Mar 11:1-9. [Epub ahead of print]
191 Genome-Wide Association Study in an Admixed Case Series Reveals IL12A as a New
Candidate in Behçet Disease. Kappen JH, Medina-Gomez C, Hagen PM, Stolk L, Estrada K,
Rivadeneira F, Uitterlinden AG, Stanford MR, Ben-Chetrit E, Wallace GR, Soylu M, Laar JA.
PLoS One. 2015 Mar 23;10(3):e0119085.
192 Behçet's Disease: Do Natural Killer Cells Play a Significant Role?
Petrushkin H, Hasan MS, Stanford MR, Fortune F, Wallace GR.
Front Immunol. 2015 Mar 24;6:134. doi: 10.3389/fimmu.2015.00134. eCollection 2015. Review
193 The Pathogenesis of Raised Intraocular Pressure in Uveitis.
Baneke AJ, Lim KS, Stanford M. Curr Eye Res. 2015 14:1-13
194 High Prevalence of Untreated Depression in Patients Accessing Low-Vision Services.
Nollett CL, Bray N, Bunce C, Casten RJ, Edwards RT, Hegel MT, Janikoun S, Jumbe SE, Ryan B,
Shearn J, Smith DJ, Stanford M, Xing W, Margrain TH. Ophthalmology. 2015 Aug 13. pii: S01616420(15)00680-6. doi: 10.1016/j.ophtha.2015.07.009. [Epub ahead of print]
INVITED LECTURES
Sandoz Advanced Neuroscience Lecture - Experimental retinal vasculitis. National Hospital, London.
January 1988.
Invited speaker: VIII Congress of European Society of Ophthalmology. Experimental uveitis - lessons
from electroretinography. Lisbon, Portugal. 1988.
Invited speaker: Recent developments in the immunopathology of intraocular inflammation - The role
of autoantibodies in experimental uveitis. Amsterdam, The Netherlands. November 1989.
Invited moderator: ARVO, Fort Lauderdale. April 1996.
Invited speaker: Pathogenesis and treatment of uveoretinitis syndromes. Gulbenkian Foundation
Meeting. Lisbon, Portugal. February 1997.
Invited speaker: Heat shock proteins in uveitis and Behçet’s disease. 4th International Symposium in
Uveitis. Yokohama, Japan. October 1997
Visiting Professor, University New South Wales, Sydney. April 1998.
Course organiser: Management of Uveoretinitis Syndromes: the difficult patient. Royal College of
Ophthalmologists Annual Congress, Glasgow. May 1998.
Is ocular toxoplasmosis an acquired disease? Danish Ophthalmological Society. Copenhagen.
October 1998.
Leucocyte trafficking in EAU/Calman training/Behçet’s disease. Gulbenkian Foundation. Portugal.
October 1998.
Is toxoplasma seen in adolescents and adults due to prenatal or postnatal infection. European
Congress on Congenital Toxoplasmosis, Vienna. June 2000.
Management of posterior uveitis. XXIX International Congress in Ophthalmology. Sydney. April 2002.
PRESENTATIONS
Retinopathy after irradiation and hyperbaric oxygen. Royal Society of Medicine. June 1984.
EAU in the black-hooded rat: differential effects of pertussis adjuvant upon choroidal and retinal
vasculitis. ARVO. May 1986.
A model of retinal vasculitis in Man. Clinical and histological features of focal lesions found in
experimental posterior uveitis in black-hooded Lister rats. 4th International Congress of Immunology
and Immunopathology of the Eye (Italy), May 1986.
Retinal Vasculitis: correlation of animal and human disease. OSUK, Oxford. June 1986.
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page16 / 26
Curriculum vitae
Miles Stanford
Experimental Retinal Vasculitis. Sydney Eye Hospital, Australia. November 1986.
Modulation of experimental retinal vasculitis using dexamethazone, cyclosporin A and prazosin.
OSUK (Cardiff). April 1987.
Passive administration of antibody to retinal S-antigen induces electroretinographic supernormality in
Lister rats. Physiological Society. November 1987.
Experimental retinal vasculitis. Sandoz Lecture. National Hospital, January 1988.
Immunology of human uveoretinitis. Dept of Immunology. Nottingham March 1988.
Experimental Uveitis - Lessons of electroretinography. 8th Congress of European Society of
Ophthalmology (Lisbon) July 1988.
Electroretinographic studies in experimental allergic uveitis. Symposium on recent developments in
immunopathology of intraocular inflammation. (Amsterdam) November 1989.
Acute anterior uveitis complicating Sweet's Syndrome. Royal Society of Medicine. (Dermatology
Section). June 1990.
A case of carcinoma-associated retinopathy. Royal Society of Medicine. December 1990.
Does the timing of removal of sutures after cataract surgery influence post-operative astigmatism?
OSUK (Glasgow). May 1991.
Macular ischaemia in posterior uveitis. OSUK (London). April 1992.
Serological analysis of EAU in F1 hybrid rats supports the immunoregulatory role of circulating
immune complexes. ARVO. May 1992.
Ocular features of inflammatory neurological disease. Royal Australian College of Ophthalmologists
Meeting. Sydney. November 1992.
Oxygen-induced retinopathy in the pigmented rat. OSUK (Birmingham). April 1993.
Heat-shock protein 65kD peptides reactive in ocular Behçet's disease are uveitogenic in Lewis rat.
ARVO. May 1993.
Ocular toxoplasmosis. King's College Hospital. May 1993.
Choroidal blood flow. Trends in Ophthalmology Meeting. St Thomas' Hospital. November 1993.
Ocular toxoplasmosis. Maidstone Eye Unit. May 1993.
Ocular toxoplasmosis. Southampton Eye Unit. March 1994.
Toxoplasmosis in South London. Oxford Congress. July 1994.
Eales disease revisited. Trends in Ophthalmology. St Thomas' Hospital. March 1995.
Current problems in ocular toxoplasmosis. Trends in Ophthalmology. St Thomas' Hospital. March
1995.
Leucocyte trafficking in EAU. BSI Spring meeting. Birmingham. 1995.
Leucocyte trafficking in EAU. ARVO meeting. Fort Lauderdale. May 1995.
Endogenous endophthalmitis. Annual Congress OSUK. Birmingham. May 1995.
Clinical features of posterior uveitis. Annual Congress OSUK. Birmingham. May 1995.
Pathogenetic mechanisms in posterior uveitis. Guide Dogs for the Blind Meeting. RSM. June 1995.
Serpiginous choroiditis - a clinicopathological study. XV European Congress of Ophthalmology. Milan.
June 1995.
Current and future imaging of uveitis syndromes. Oxford Eye Unit. October 1995.
Current concepts in ocular toxoplasmosis. RSM Meeting. February 1996.
Current aspects of ocular toxoplasmosis. East Kent Ophthalmological Society. Kent and Canterbury
Hospital. February 1996.
Current and future methods of retinal imaging. NE Kent and SE London Optometrists Study Day. April
1996.
Antiretinal and antitoxoplasma antibodies in acute symptomatic toxoplasma retinochoroiditis. ARVO
Meeting. Fort Lauderdale. April 1996.
Urinary neopterin levels: a potential marker of disease activity in retinal vasculitis. Annual College
Ophthalmologists Meeting. May 1996.
Current aspects of ocular toxoplasmosis. Toxoplasma '96. Dublin. May 1996.
The epidemiology of ocular toxoplasmosis. International Uveitis Study Group Meeting. September
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page17 / 26
Curriculum vitae
Miles Stanford
1996.
Ocular toxoplasmosis. Postgraduate Teaching Day. Leeds. September 1996.
Trends in imaging of the posterior segment in uveoretinitis. Trends in Ophthalmology Meeting. St
Thomas' Hospital. November 1996.
The British Ophthalmological Surveillance Unit. YOT Club Meeting. March 1997.
Acute toxoplasma retinochoroiditis in the UK - a Four Region Study. IV Annual Meeting European
Research Network on Congenital Toxoplasmosis. Toulouse. June 1997.
Ocular Behçet's disease. 1st International Symposium on Behçet's Disease in Jordan. Amman. June
1997.
Ocular toxoplasmosis - epidemiology and clinical features. Great Ormond Street. June 1997.
Current methods for imaging the fundus in ocular inflammatory disease. East Anglian Regional Study
Day. Ipswich. June 1997.
Harada's disease complicating alopecia. Medical Retinal Group Meeting. Oxford. July 1997.
The Genetics of Uveitis. Trends in Ophthalmology. St Thomas’ Hospital. November 1997.
Endogenous endophthalmitis. Severe ocular infections course. Moorfields Eye Hospital. November
1997.
Current concepts in ocular toxoplasmosis. Regional Ophthalmology Meeting. Tunbridge Wells.
December 1997.
Imaging in uveitis. Western Ophthalmic Hospital. February 1998.
Current imaging and management of uveoretinitis. East Glamorgan Regional Study Day. January
1998.
Discussant. Ocular findings in congenital toxoplasmosis. European Network on Study of Congenital
Toxoplasmosis (EMSCOTT). Paris. March 1998.
Heat shock proteins and Behçet’s disease. University New South Wales. Sydney. April 1998.
Management of uveoretinitis syndromes: the patient with an ischaemic retina. Royal College
Ophthalmologists Annual Congress. April 1998.
HLA associations in retinal vasculitis. ARVO. Fort Lauderdale. May 1998.
Fluorescein angiography in posterior uveitis. International Congress Ophthalmic Photographers.
Edinburgh. September 1998.
What’s new in uveitis? Trends in Ophthalmology meeting. St Thomas’ Hospital, London. November
1998.
The genetics of uveitis. Section of Ophthalmology. RSM. November 1998.
Current concepts in toxoplasmosis. Bristol Eye Unit. November 1998.
Endogenous endophthalmitis. Severe ocular infections course. Moorfields, London. November 1998.
Behçet’s disease. Oxford Eye Unit. February 1999.
Uveitis course. Moorfields Eye Hospital. Intermediate and Endogenous endophthalmitis. March 1999.
Advances in Behçet’s disease. Tennant Institute Ophthalmology. Glasgow. February 1999.
Medical Ophthalmology and the Skin. St John’s Institute of Dermatology. April 1999.
Chairman, Free Paper Session. Royal College of Ophthalmologists. May 1999.
Ocular Toxoplasmosis. Birmingham Eye Unit. May 1999.
British Ophthalmic Surveillance Unit. Irish College of Ophthalmologists. May 1999.
Genetics of Uveitis. Manchester Eye Hospital. June 1999.
Genetics of Uveitis. Western Eye Unit. July 1999.
Endogenous endophthalmitis. Severe Infections course. Moorfields Eye Hospital. November 1999.
Tuberculosis retinitis. Trends in Ophthalmology. St Thomas’ Hospital. November 1999.
Case reports/management of retinal vasculitis. British Uveitis Group. Birmingham. February 2000.
Endogenous endophthalmitis/intermediate uveitis. Moorfields Uveitis Course. March 2000.
Expert agreement in the diagnosis of toxoplasma retinochoroiditis. ARVO, Fort Lauderdale. May
2000.
Visual outcome in retinal vasculitis. RCOphth meeting. Harrogate. May 2000.
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page18 / 26
Curriculum vitae
Miles Stanford
Epidemiology of ocular toxoplasmosis. European Conference on Congenital Toxoplasmosis. Vienna.
July 2000.
Ocular toxoplasmosis. Nottingham Eye Unit. October 2000
.
Diagnostic test in uveoretinitis syndromes. Trends in Ophthalmology. St Thomas’ Hospital. November
2000.
Current concepts in ocular toxoplasmosis. North of England Ophthalmological Society. Leeds.
November 2000.
Acute retinal necrosis. Southern Ophthalmological Society. St Thomas’ Hospital. November 2000.
Heat shock proteins in Behçet's disease. UK Behçet's Disease Forum. Leeds. February 2001.
The diagnosis of uveoretinitis. Ophthalmic Regional Study Day. St Thomas' Hospital. March 2001.
Symptoms and signs, intermediate uveitis and endogenous endophthalmitis. Moorfields Uveitis
Course. March 2001.
Behçet’s disease. Dept GU Medicine, St Thomas’ Hospital. October 2001.
Inflammatory bowel disease and the eye. London Inflammatory Bowel Disease Forum. October 2001.
Chairman. Endogenous endophthalmitis. Trends in Ophthalmology. November 2001.
Intermediate Uveitis. Ophthalmology Section. RSM. January 2002.
‘Beyond the BD8’. Organizer and chair. Ophthalmology Regional Study Day. St Thomas’ Hospital.
March 2002.
Organizer and Chair. Cutting Edge in Glaucoma Research. GDBA Symposium. RSM. April 2002.
Organizer and Chair. Update on Intraocular Inflammation. Royal College of Ophthalmologists Meeting.
Manchester. May 2002.
Antibiotic treatment in toxoplasma retinochoroiditis. EMSCOTT meeting. Egham May 2002
Intermediate Uveitis and Endogenous Endophthalmitis. Moorfields Uveitis Course.May 2002
Investigation and Management of intraocular inflammation. Brighton Teaching Day. June 2002
Phase 1/II trial of HSP-peptide in patients with Behcet’s disease and uveitis. 10th International
Conference on Behcet’s disease. Berlin June 2002
The treatment of toxoplasma retinochoroiditis. Trends in Ophthalmology meeting. St Thomas’
Hospital. Nov 2002
Investigation and management of uveitis. Southampton Eye Unit Feb 2003
Endogenous endophthalmitis. Retinal Infections Course. RCOphth meeting Birmingham May 2003
Corneal Melts. Regional Study Day. Sidcup June 2003
Chairman Scientific session. International Conference on Toxoplasmosis. Copenhagen June 2003
Recent Advances in Behcet’s Disease. Syrian Ophthalmological Society. Damascus Sept 2003
The Investigation of Uveitis. Bristol Eye Unit Nov 2003
Rapporteur, EUROTOXO Toxoplasma Prevention Project, Bordeaux, Feb 2004
Chair, Neuro-Ophthalmology Regional Study day, St Thomas’ Hospital. March 2004
Endogenous Endophthalmitis, Regional Study Day, Redhill. March 2004
Recent advances in Ocular Toxoplasmosis, 2nd Pan Arabic Ophthalmology Congress. Damascus.
April 2004
Visual Fields in Toxoplasma Retinochoroiditis. ARVO. Ft Lauderdale. Florida April 2004.
National Survey of Ocular Toxoplasmosis. RCOphth Annual Congress. Manchester. May 2004.
Intermediate Uveitis/Endogenous endophthalmitis. Moorfields Uveitis Course. May 2004.
Ocular findings in Congenital Toxoplasmosis. EMSCOT meeting. Institute of Child Health. June 2004.
Investigation of uveitis/Intermediate Uveitis/Endogenous endophthalmitis. Moorfields Uveitis Course.
Slovenia Sept 2004
Levels of IL-15 in the serum of patients with Behcet’s disease. XI International Conference on
Behcet’s Disease. Antalya. Turkey. Oct 2004
Endogenous Endophthalmitis. ‘VR in a day’ St Thomas’ Hospital London Feb 2005
Visiting Professor, Jules Stein Eye Institute, UCLA, California, April 2005
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page19 / 26
Curriculum vitae
Miles Stanford
Invited Speaker, EULAR Congress. Vienna, June 2005
Moorfields Uveitis Course. Reggio Emilio Italy June 2005
Invited Speaker Syrian Ophthalmological Society. Damascus July 2005
Invited Speaker EVER meeting. Faro, Portugal Sept 2005
RCOphth College Seminar. Ocular Toxoplasmosis. Oct 2005
Panel Member EUROTOXO. Bordeaux Oct 2005
Speaker. Trends in Ophthalmology meeting. St Thomas’ Hospital Nov 2005
Speaker: South Thames Regional Study day King’s College Hospital Dec 2005
Speaker, Pathology Refresher Course for MRCOphth, STH Feb 2006
Speaker Medical Ophthalmology Society UK (MOSUK) Guy’s Hospital Mar 2006
Organiser Regional Neuro-ophthalmology Study Day, St Thomas’ Hospital March 2006
Speaker. 1st Jordanian Rheumatology Conference. Amman. April 2006
Speaker. University Department of Ophthalmology, Aleppo, Syria May 2006
Panel member, International consensus panel on the use of anti-TNF agents in Behcet’s disease.
Athens May 2006
Symposium Chair, British Ophthalmological Surveillance Unit, Royal College Ophthalmologists
Annual Congress Manchester May 2006
Speaker. ‘Fundal signs in systemic vasculitis’ Royal College Ophthalmologists Annual Congress May
2006
Speaker ‘Ocular toxoplasmosis’ Royal Free Hospital July 2006
Speaker Pt 1 FRCOphth Course ‘Ocular Immunology’ St Thomas’ Hospital Aug 2006
Session Chairman 12th International conference on Behcet’s disease. Lisbon Sept 2006
Speaker, Birdshot Chorioretinopathy Workshop, Paris Oct 2006
Panellist, EULAR guidelines for management of Behcet’s disease, Zurich Oct 2006
Speaker Pt 1 FRCOphth Course ‘Ocular Immunology’ St Thomas’ Hospital Jan 2007
Recent Advances in Ocular Toxoplasmosis. Brighton Eye Unit Feb 2007
Epidemiology of toxoplasmosis. London School for Hospital and Tropical Medicine. Mar 2007
Endogenous endophthalmitis. VR in a day Course. St Thomas’ hospital. April 2007
A Case of Ocular Toxoplasmosis UK NEQAS meeting. Royal College of Nursing May 2007
Treatment Evidence – what is needed. Presenter and session chair 3rd International Conference on
Congenital Toxoplasmosis. Armenia. Columbia. May 2007
Bacterial and fungal infections of the eye. Royal College Ophthalmologists Annual Meeting
Birmingham. May 2007
Retinal manifestations of giant cell arteritis and their differential diagnosis. SOE meeting Vienna June
2007
The epidemiology and pre-operative management of cataract in uveitic eyes. SOE meeting Vienna
June 2007
Ocular Toxoplasmosis. Master’s symposium. Oxford Ophthalmological Congress. July 2007
Differential diagnosis of intermediate uveitis. Third Moorfields Uveitis Course. London July 2007
Ocular toxoplasmosis. Third Moorfields Uveitis Course. London July 2007
Standard Treatment for Behcet’s Disease. 9th International Congress Intraocular Inflammation
Society. Paris Sept 2007
New Concepts in ocular toxoplasmosis. 13th Bury St Edmunds Symposium. Oct 2007
The role of cytokine gene polymorphisms in uveitis. RSM Ophthalmology section Nov 2007
Challenges in the control of toxoplasmosis MSc Community Ophthalmology LSHTM Feb 2008
The intraocular consequences of viral infections STH Regional Study Day March 2008
The nomenclature and classification of retinal vasculitis Ettal, Munich April 2008
Syphilis; a resurgent and treatable cause of uveitis. Euretina Vienna May 2008
Neurological concomitants of uveitis; multiple sclerosis. Euretina Vienna May 2008
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page20 / 26
Curriculum vitae
Miles Stanford
Session Chair 13th International Behcet’s Disease meeting. Klagenfurt. Austria May 2008
The intraocular consequences of viral infection. Syrian Ophthalmological Society June 2008
New drugs for uveitis. MOSUK Oxford July 2008
Management of posterior uveitis. Med Ret Group Panellist Oxford July 2008
Viral infections in the eye and their treatment, New drugs in uveitis, Mechanisms and treatment of
uveitis glaucoma and Intermediate uveitis and MS. Columbian Ophthalmological Society. Cartagena.
Aug 2008
Toxoplasmosis: clinical features and treatment efficacy. Vision Research. Bristol Sept 2008
Treatment for ocular toxoplasmosis – Current Evidence. Toxoplasma Centennial Conference. Buzios
Brazil Sept 2008
Endophthalmitis Microbiology group STH Nov 2008
Endophthalmitis Southern Ophthalmological Society Dec 2008
Ophthalmological emergencies in connective tissue diseases RSM Rheumatology Meeting Jan 2009
Chair AM session Trends in Ophthalmology Meeting Jan 2009
Endogenous Endophthalmitis. VR in a Day Course Feb 2009
Challenges in the control of toxoplasmosis and Uveitis. LSTHM Community Eye Course Mar 2009
Scleritis. Regional Study day STH Mar 2009
Intraocular Infections, F1 Teaching, STH April 2009
The role of the trainee in research. Tunbridge Wells R+D Meeting May 2009
Endogenous endophthalmitis Retinal Infections course SOE Amsterdam June 2009
Controversies in Ophthalmology Symposium. – Treatment of ocular toxoplasmosis. SOE Amsterdam
June 2009
Ocular toxoplasmosis in children. World Paediatric Ophthalmology Congress. Barcelona Sept 2009
Endophthalmitis. SpR in Microbiology/Virology Club. Sept 2009
Ocular Toxoplasmosis. Midland Ophthalmological Society October 2009
The pathophysiological substrate of ocular inflammatory disease. Oxford Alumnus meeting.
December 2009
Chair – Medical Ophthalmology cases. Trends in Ophthalmology. Feb 2010
Endophthalmitis. RSM Ophthalmology Section meeting Feb 2010
Challenges in the control of toxoplasmosis and uveitis. LSTMH Eye Community MSc course March
2010
The eye in systemic vasculitis – MOSUK March 2010
Academic Ophthalmology – RSM undergraduate meeting March 2010
Toxoplasmosis – 68th Panhellenic Ophthalmological society May 2010
Atypical forms of toxoplasmosis – WOC Berlin June 2010
Organiser and Speaker “Behcet’s in a day” July 2010
Organiser and Speaker 14th International Behcet’s Disease Society Congress. London July 2010
Tubulointerstitial nephritis and uveitis. Moorfields Uveitis Course July 2010
Uveitis course – Euretina. Paris September 2010
Endophthalmitis. City university MSc course. September 2010
Symptoms, signs and prognosis. Birdshot Choroiditis Patients day. London Sept 2010
Cataract surgery in patients with uveitis. Damascus Sept 2010
Endogenous endophthalmitis. Microbiology meeting. St George’s Hospital. Oct 2010
Update on Ocular Toxoplasmosis. Glasgow College of Surgeons Jan 2011
The eye in systemic vasculitis. Trends in Ophthalmology Royal Society. Feb 2011
Challenges in toxoplasmosis. Uveitis. MSc Community Eye Course. LSTHM Feb 2011
The Eye in Systemic vasculitis. Western Eye Hospital. Feb 2011
Organiser Regional study day – Neuro-ophthalmology. St Thomas’ Hospital Mar 2011
Recent advances in toxoplasmosis / intraocular effects of viruses. Syrian Ophthalmological society.
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page21 / 26
Curriculum vitae
Miles Stanford
March 2011
Challenges in the control of ocular toxoplasmosis. STH Microbiology March 2011
Academic and Medical Ophthalmology. RSM Undergraduate Congress March 2011
Uveitis. RSM Meeting Ophthalmology for physicians. March 2011
Tuberculosis Euretina Course London may 2011
Serpiginous Choroiditis. Euretina Course London May 2011
Vitrectomy is a cure for uveitis. Great debate Euretina May 2011
Current and future treatments for Behcet’s disease. Euretina May 2011
Intermediate Uveitis. EUPO Course SOE Geneva June 2011
The role of cytokine gene polymorphisms in uveitis. SOE Geneva Jun 2011
Red Eyes That matter in patients with general medical conditions. RCP Oct 2011
Ocular toxoplasmosis/Behcet’s disease – Maltese Ophthalmological Society Oct 2011
Ocular Tuberculosis. Regional Study day Kings College Hospital Dec 2011
Chair – Medical Ophthalmology cases. Trends in Ophthalmology. Feb 2012
Challenges in the control of toxoplasmosis and uveitis. LSTMH Eye Community MSc course March
2012
Treatment of Birdshot Chorioretinopathy. Birdshot Patients Day March 2012
Ocular toxoplasmosis. MOSUK March 2012
Ocular manifestations of Behcet’s disease. SW Thames Rheumatology group. June 2012
The Eye in rheumatic disease. Ten Topics in Rheumatology. St Thomas’Hospital July 2012
Tuberculosis/serpiginous choroidopathy. Euretina Uveitis Course. Milan Sept 2012
The eye in spondyloartropathies. APLAR Jordan Sept 2012
Organiser treatment and investigation ocular inflammation. College Symposium Sept 2012
Intermediate Uveitis. College Symposium Sept 2012
Behcet’s in a day – Training day. Organiser and ocular manifestations of Behcet’s disease. Nov 2012
Retinal Infections. NW Thames Ophthalmology Study Day. Dec 2012
Challenges in the control of toxoplasmosis and uveitis. LSTMH Eye Community MSc course March
2013
Chair – Medical Ophthalmology cases. Trends in Ophthalmology. Feb 2013
Toxoplasmosis Regional Study day St Thomas’ Hospital Mar 23013
Ocular Behcet’s disease. RCOphth Congress May 2013
The many guises of choroiditis RCOphth Congress May 2013
Current and novel therapies for ocular disease. 11th World Congress Inflammation. Brazil Sept 2013
Toxoplasmosis, tuberculosis; Serpiginous choroiditis. Euretina Uveitis Course Hamburg Sept 2013
Ocular Toxoplasmosis. SAS Ophthalmology Conference London Oct 2013
Diagnostic signs in retinal vasculitis, ocular toxoplasmosis, standard treatment for uveitis. Uveitis
course. 47th Annual congress Turkish Opthalmology Society. Nov 2013
Organiser and speaker “Behcet’s disease in a day”. London Nov 2013
Tuberculosis and the eye. Chest Dept. St Mary’s Hospital Jan 2014
Chair Medical Eye Unit cases. Trends in Ophthalmology. Royal Society London Feb 2014
Organiser and speaker “Behcet’s disease “ symposium. MOSUK St Thomas’ Hospital London March
2014
Organiser and speaker S Thames Regional Study Day March 2014
Organiser and speaker “Skins, eyes and chests” RSM Ophthalmology Section May 2014
RCOphth Annual Congress, Birmingham May 2014 – Hypertension and the eye, uveitic macular
oedema, When to ask for help.
Ophthalmic emergencies in rheumatic disease: when to refer. Rheumatology study day STH June
2014
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page22 / 26
Curriculum vitae
Miles Stanford
Tuberculosis and the Eye. Euretina teaching course London Sept 2014
Behcet’s disease and the eye Euretina teaching course London Sept 2014
Paediatric retinal infections. World Congress paediatric ophthalmology London Sept 2014
Chair. Session on modern therapy for Behcet’s disease. 16th Internatiomal Congress Behcets
disease. Paris Sept 2014
Pathogenesisof macular oedema. 10th Annual Yorkshire Medical Retina Meeting, Leeds Nov 2014
Case Presentation. National Behcet’s in a Day meeting. Bart’s Nov 2014
Chair Medical ophthalmology cases and 40 years of Trends. Trends in Ophthalmology feb 2015
Epidemiology of toxoplasma and Uveitis. Community Eye health course LSTHM feb 2015
Medical Emergencies in Ophthalmology. RCOphth Seminar Feb 2015
The eye in rheumatology. Rheumatology Study day UCLH Mar 2015
Organiser and speaker. Regional study day S Thames ophthalmology Mar 2015
Invited Speaker 12th Jordanian Ophthalmological Congress. May 2015
Organiser and speaker “The Spotted Fundus”. RCOphth Annual Congress Liverpool May 2015
An update on ocular toxoplasmosis. Medical Retina Group. Oxford. July 2015
Participant and Session chair. “Next generation thinking in treatment of inflammatory eye disease.”
Munich July 2015
Viral Retinitis. Euretina Uveitis Course. Nice Sept 2015
Medical retina emergencies. British Association of Emergency Ophthalmology. RCP Oct 2015
Session Chair. 3rd National Birdshot Patient’s Day. Nov 2015
Chair and organiser. Behcet’s in a Day. Royal London Nov 2015
Projects
CURRENT AND RECENT TRIALS
1) Does the addition of subcutaneous interferon alpha2b for 6 months only to the treatment of
Behcet’s disease significantly reduce the number of patients requiring immunosuppressive agents to
control their disease over the following 3 years. Multicentre trial (CI Moorfields Eye Hospital, also
Royal Brompton, Hammersmith hospitals) PI
2) DEX PS DDS Applicator system in patients with anterior uveitis. International Multicentre study
Allergan (through Charles River laboratories) PI end Aug 2009
3) DEX PS DDS Applicator system in patients with intermediate uveitis. International Multicentre study
Allergan (through Charles River laboratories) PI end Aug 2009
4) Use of a long term slow release applicator of fluocetonide (Retisert)in patients with posterior uveitis.
International multicentre trial. Bausch and Lomb PI end Aug 2005
5) A double masked,placebo-controlled, parallel group, multicentre, dose ranging study to assess the
efficacy and safety of LX211 as therapy in subjects with active sight threatening, non-infectious
intermediate and posterior uveitis. Lux Biosciences (through PRA associates) PI end Aug 2009
6) A double masked,placebo-controlled, parallel group, multicentre, dose ranging study to assess the
efficacy and safety of LX211 as therapy in subjects with quiescent sight threatening, non-infectious
intermediate and posterior uveitis. Lux Biosciences (through PRA associates) PI end Aug 2009
7) A 24-week multicentre, randomized, double masked, placebo controlled, dose-ranging phase III
study of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic
immunosuppression in patients with quiescent, non-infectious intermediate, posterior or panuveitis
(ENDURE Study) Novartis PI end February 2011
8) A 24-week multicentre, randomized, double masked, placebo controlled, dose-ranging phase III
study of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic
immunosuppression in patients with active, non-infectious intermediate, posterior or panuveitis
(INSURE Study) Novartis PI end February 2011
9) LX211-11: A multi-center, double-masked, parallel group, placebo-controlled study to assess the
efficacy and safety of voclosporin as therapy in subjects with actve noninfectious intermediate,
posterior and panuveitis. Sponsors Lux Biosciences. PI end July 2012
10) A Phase III, multinational, multicenter, randomized, double-masked study assessing the safety
and efficacy of intravitreal injections of DE-109 (three doses) for the treatment of active, non-infectious
uveitis of the posterior segment of the eye. Sponsor Santen. REC 11/LO/1226. R+D reg GSTFT 2144.
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page23 / 26
Curriculum vitae
Miles Stanford
EudraCTnumber 2011-001595-19 PI
11) A randomized double-masked, placebo-controlled study of the efficacy of gevokizumab in the
treatment of patients with Behcet’s Disease uveitis. REC 12/LO/1650. R+D GSTFT 2467 CI end Dec
2015
12) Evaluation and immune response to auto-antigens and apitopes in patients with uveitis. Sponsor
Apitope International NV REC 13/LO/0971. R+D GSTFT2865 CI
13) A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy
Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects with Chronic Non-Infectious
Uveitis Affecting the Posterior Segment of the Eye. REC Number: 13/LO/1320 EudraCT Number:
2013-001810-14 R&D GFTFT 2965. PI
GRANTS
1. MR Stanford
Autoimmunity in retinal inflammatory disease.
Iris Fund for the Prevention of Blindness. 1996-2000.
£256,470 + £52,625.87 from 1.1.97.
2. with McCartney ACE and Graham EM.
Pathogenesis and early diagnosis of viral and protozoal retinal infections.
Iris Fund for the Prevention of Blindness. 1996-1999.
£239,441
Extended 1999-2000
£31,100
3. with Graham EM and Shilling JS.
FITC dextran leakage from age related disciform membranes in vivo.
Genentech Pharmaceuticals L.A. 1996.
£30,000
4. with Marshall J, Heacock G, Shilling J and McHugh D.
Telemedicine and screening for diabetic retinopathy.
National Lotteries Charities Board (Iris Fund for the Prevention of Blindness). 1997-2001.
£327,483
5. with Verity DH and Wallace GR.
The role of tumour necrosis factor in the pathogenesis of Behçet's disease.
TFC Frost Charitable Foundation. 1997-1998.
£36,215
Extended 1998-1999
£40,426
6. with Graham EM and Wallace GR.
The pathogenic and predictive significance of haemostatic activation in ischaemic retinal
vasculitis.
Iris Fund for the Prevention of Blindness. 1998-2001.
£238,797
7. with Lehner T.
Prevention of experimental and human uveitis by oral tolerance with heat shock
protein derived peptide, linked to cholera B subunit.
Iris Fund for the Prevention of Blindness. 1998-2001.
£140,000
8. with Wallace GR.
Matrix metalloproteinases in the maintenance of ocular immune privilege.
Research (Endowments) Committee. 1998-1999.
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page24 / 26
Curriculum vitae
Miles Stanford
£29,000
9. Stanford MR.
Salary support for Reader in Ophthalmology.
Iris Fund for Prevention of Blindness. July 2000-2001.
£71,360
Extended July 01 – June 02
£74,511
10. with Wallace GR and Graham EM.
The role of macrophages in the induction of uveoretinitis.
Iris Fund for Prevention of Blindness. 1 July 2000-30 June 2001.
£87,447
11 with Subak-Sharpe I and Wallace GR.
The role of the macrophage in retinal repair.
Guy’s and St Thomas’ Charitable Foundation. 1 May 2001-31 April 2003.
£94,158
12 with Wallace GR, Vaughan RW and Graham EM.
The relationship of gene polymorphisms to disease outcome in patients with uveitis.
Guide Dogs for the Blind Association. 2000-2002.
£67,353
13 with Wallace G R
Infectivity of Toxoplasma gondii in retinal Muller and microglial cells
Iris Fund for Prevention of Blindness 2003-05
£105,187
14 with RE Gilbert (PI), Cortino Borja, Dunn D, Freeman K, Petersen E, Salt AT. Outcomes in
Congenital Toxoplasmosis.
National Eye Institute NEI 1 R03EY015287 01/01/04-01/01/06
$127,831
15 with Wallace GR, Hayday A, Vaughan R, Graham E.
The influence of MICA allelic forms on the activation status of immune cells in Behcet’s disease
British Eye Research Fund. 01/01/05-31/12/06
£101,314
16 to support PhD of Ms Seema Shafi
Fight for Sight 01/09/07 – 31/08/08
£11,000
17 with Christopher Hammond, Tim Spector. The genetics of common age related eye disease
NIHR Senior clinical research Fellowship 01/10/08 – 30/09/13
£630,237
18 with Wallace GR, Murray PI. A genetic basis for predicitng outcome in intermediate uvetis. Guide
Dogs for the Blind 01/02/10 – 31/01/12
£116,051 . R+D RJ110/N317
19 with Margain T, Smith TJ, Tudor Edwards R. Depression in visual impairment trial (DEPVIT) Guide
Dogs for the Blind 09/09/10- 01/08/13
£206,635 R+D ref 11/WA//0014
Memberships
Programme Director, Calman SpR Training (Ophthalmology) SE Thames. 1996-2002
Chairman, British Ophthalmological Surveillance Unit. 1996Member, Royal College of Ophthalmologists Audit Committee. 1996-1999
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page25 / 26
Curriculum vitae
Miles Stanford
Member, Royal College of Ophthalmologists Scientific Committee. 1996-2006
Member, Royal College of Ophthalmologists Regional Advisers/Programme Directors Committee.
1996-2002
Member, Royal College of Ophthalmologists Training Committee 2005-10
Member, Royal College of Ophthalmologists Equivalence of Training Committee 2005Member RCOphth NCCEA committee 2008
Member, British Uveitis Group. 1998Member, British Behçet’s Disease Forum. 1998Member, Scientific Board, Retinitis Pigmentosa Fighting Blindness. 1999-2015
Member, Scientific Board, British Council for Prevention of Blindness, 2005-12
Member, Scientific Advisory Committee, Guide Dogs for the Blind Association. 1999Member International Behcet’s Disease Society 1999Executive Board International Behcet’s disease Society. 2012Trustee and Council member, Guide Dogs for the Blind Association July 2003-12
Panellist, EULAR recommendations for management of Behçet’s Disease 2006 and 2015
Section Editor, Ophthalmology International. 2005-2011
Member, Ulverscroft Research Group Advisory Board 2007Corresponding Member, Columbian Ophthalmological Society 2008
Panellist/judge Medical Futures – Innovations in Ophthalmology 2008
Panellist Rare Autoimmune Diseases Expert Working Group 2011Chair, Scientific Advisory Board, Birdshot Patients Society 2012Member, Specialist Commissioning Committee, RCOphth 2012Other Relevant Information
PRIZES AND AWARDS
Ware Prize in Pathology March 1978
MRC Training Awards Fellowship August 1985
Research (Endowments) Fellowship April 1985
Poster Prize (Alcon. RSM) 1985
Poster Prize (Alcon. RSM) 1987
ACCEA Bronze Award April 2007 renewed 2011
11/3/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page26 / 26